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Abstract
Chronic Myeloid Leukemia (CML) has served as a model for how cancer can be
selectively targeted with advanced forms of chemotherapies known as kinase inhibitors. Such
new therapies have significantly altered the field of oncology and have led to monumental
increases in both survival rates and quality of life for cancer patients. However, approximately
one-third of CML patients will go on to develop drug resistance against major kinases inhibitors.
Along with this, other cancers are showing increased incidences of drug resistance.
Understanding how these cancers, such as CML, overcome drug sensitivity is of major
importance within the clinic. To predict potential cell signaling pathways utilized in drug
resistant CML, we generated a highly drug resistant T315I BCR-Abl mutant CML cell line from
the already established KCL-22 cell line. With our established cell line we analyzed the activity
of several cell signaling pathways that serve roles in controlling cellular proliferation, cellular
differentiation, and cell death. In contrast to the wild type KCL-22 cell line, we were able to
identify MEK1/2 and mTOR dependency within the drug resistant mutant. These findings
allowed us conclude that FDA approved kinase inhibitors Trametinib (a MEK1/2 inhibitor) and
Temsirolimus (an mTOR inhibitor) may hold therapeutic value in selectively targeting T315I
BCR-Abl CML tumor cells. Lastly, using a series of bioinformatics tools such as PROVEAN
and SIFT, we analyzed the genomic landscape of both the wild type and artificially established
drug resistant CML mutant in order to identify genetic alterations that may be associated with
drug insensitivity. From this genomic analysis we were able to identify several novel mutations
within the drug resistant mutant that occur within key regulatory sites of various cell signaling
molecules. In conclusion, CML drug insensitivity can be overcome by targeting downstream

x

targets of BCR-Abl such as MEK1/2 or mTOR, and various mutations besides the T315I BCRAbl variant may contribute to drug insensitivity.

xi

Chapter I: General Introduction
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1.1 Cancer and Society
Cancer is a major cause of death worldwide (U.S. Cancer Statistics Working Group, 2013),
and is the leading cause of death for Hispanics (Kochanek, 2009). Sophisticated statistical studies
supported by the World Health Organization predict cancer to continue to be amongst the top
leading causes of global mortality from present day to the year 2030 (Mathers, 2006).
Although trends in cancer rates are predicted to increase, deaths due to cancer are
decreasing in developed countries. This decrease is largely due to medical advances, such as the
use of tyrosine kinase inhibitors (TKIs) in the treatment of cancer. However, leukemia has been
identified as a leading cause of childhood deaths in both developed and underdeveloped countries
(Chatenoud, 2010).
Within the United States, cancer rates continue to rise. The National Institutes of Health
(NIH) has estimated that $86.6 billion dollars is spent annually on cancer treatment in the United
States. Of the $86.6 billion dollars, cancer treatment expenditures in Texas alone account for
nearly $7.7 billion dollars, with the Upper Rio Grande and West Texas regions accumulating $417
million dollars in cancer treatment per year. Limiting unnecessary costs on failed treatments, while
producing more effective treatments for patients, has become a central issue for both state and
national authorities. In El Paso County alone, there were an estimated 3,071 new cancer cases, and
1,063 cancer deaths for 2013. Leukemia and Lymphomas are amongst the leading childhood and
adolescent cancers in El Paso (Texas Department of State Health Services, 2013).
These findings have emphasized the importance for further investigation into the exact
mechanisms that cause and drive cancer, and more importantly, the underlying causes of drug
resistant cancers. With the discovery of Imatinib, chronic myeloid leukemia has served as a model
for understanding how a cancer can be selectively targeted. Along with being a pioneer of
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personalized cancer treatment, chronic myeloid leukemia has also served as a model for how
cancer can evolve (Melo, 2007). Since the newer generation of TKIs are showing promise for
cancer treatment, it is also important to attempt to identify as many pathways these small molecule
inhibitors act on. Along with this statement, it is also important to identify any genetic
aberrations that may lead to the production of neoplasms. Developing new ways of screening
cancer cells against various drugs, and finding ways to navigate the cancer genome, are of
utter importance for the progression of successful new cancer treatment.

1.2 Cancer and Cell Signaling
Within the healthy individual, various cell types are constantly utilizing a vast array of
signaling networks in order to maintain homeostasis. Proper functioning of these networks relies
on the activity of key proteins. Aberrant changes within the amino acid sequence can lead to
alterations in structure and dysfunction of the protein. Such changes can lead to abnormal signaling
networks within the cell.
Cancer cells must develop the ability to escape immune surveillance as well as sustain
rapid replication. Neoplasms are capable of performing such tasks through the utilization of
intracellular pathways such as the JAK/STAT, MAPK/ERK, PI3K/Akt, and TGF-β pathways.
Each pathway has it’s own function in disease progression, and in some cases is utilized more
frequently throughout different cancers (Dreesen, 2007).
Much remains to be discovered about these mechanisms, however the past ten years has
seen significant advancements in cancer research. Such research has established a centralized
rationale of what characteristics abnormal cells must possess to be classified as cancer. These
characteristics, or “Hallmarks of Cancer”, are traits that allow the cancer cell to flourish (Figure
1.1). The first of the six accepted cancer traits is the ability to resist cell death. This can result from
3

various alterations of the PI3K/AKT pathway which drive increased proliferation and pro-survival
signals. Cancers that rely heavily on aberrant PI3K/AKT pathway signaling include: lymphoma,
thyroid cancer, ovarian cancer, and renal-cell carcinoma (Vivanco, 2002). Additionally, the cancer
cell must establish proliferative signaling while at the same time achieve replicative immortality
and evade growth suppression or death by the immune system. These three hallmarks are seen in
leukemia/lymphoma phenotypes due to the alteration of transmembrane proteins such as NOTCH
receptors, and others alike (Aster, 2011). Furthermore, the cancer cell must activate a system that
will allow itself to spread (metastasize) to other parts of the body, and establish a source of
nutrients by inducing angiogenesis. This aspect of cancer is least understood, but new research
continues to highlight the use of cytokines in metastatic progression. (Hanahan, 2011).

Figure 1.1 Six Hallmark Characteristics of a Cancer Cell. Requirements
for a cell to be considered cancerous six hallmarks must be accomplished.
(Hanahan, 2011).
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1.2.1 Kinase inhibitors and Cancer
The disease specific kinase inhibitors have to offer in treating cancer highlights the
importance to continue screening novel compounds for cancer therapy use. A major advancement
for cancer treatment was the development of chemotherapy. However, many of the drugs used for
conventional chemotherapy have limited success and are not selective in treating cancer. A major
flaw in this form of chemotherapy is its inability to discriminate between normal and abnormal
cells. This limitation associated with chemotherapy treatment results in the patient experiencing
negative side effects. Realizing the limitations of chemotherapy, cancer scientists and oncologists
have developed ways to selectively target aberrant cell signaling networks present in cells. Such
devices include the use of antibodies, antisense, inhibitors of growth factor receptors and tyrosine
kinases. Tyrosine kinases serve major roles in normal and cancerous cell growth. Many pathways
utilize tyrosine kinase signaling in order to carry out specific functions. Kinases are enzymes that
can range from peptide to lipid molecules that are capable of transferring a phosphate group from
adenosine triphosphate (ATP) or guanosine triphosphate (GTP) to the hydroxyl side chain of
serine, threonine, or tyrosine residues on target proteins. Transfer of phosphate groups provides the
energy needed to drive the signaling process. Since tyrosine kinases serve such important roles in
these cancers, scientists have developed therapies that are moderately selective in inhibiting
aberrant tyrosine kinase function. One success of these new chemotherapies developed includes
that of a BCR-ABL tyrosine kinase inhibitor, imatinib mesylate (Gleevec, Novartis). Gleevec was
the pioneer of targeted cancer treatment, and has had major success in treating BCR-ABL positive
cancer patients (Aora, 2005). Sorafenib (Nexavar; Bayer Pharmaceuticals) is another landmark for
cancer treatment utilizing kinase inhibitors. Sorafenib was developed in 1994 after a large drug
screen and was shown to inhibit the proteins Raf-1 and B-Raf. Unlike imatinib, sorafenib has been
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shown to block the autophosphorylation of several receptor tyrosine kinases (VEGFR1, 2, and 3,
PDGFRβ, c-Kit, and RET), and is used mainly for the treatment of advanced renal cell carcinoma
(Wilhelm, 2007).
Since the installation of the tyrosine kinase inhibitor imatinib, many other kinase inhibiting
molecules, including sorafenib, have been developed. Since 2001, more than 10,000 kinase
inhibitor patents have been filed. Problems that persist in using kinase inhibitors for cancer
treatment are that many cancers utilize more than one kinase to survive. Additionally, the networks
used by these cancers are also used by normal cell types, which can lead to drug toxicity side
effects when targeted for cancer treatment by kinase inhibitors. To avoid drug toxicity, kinase
inhibitors must offer high selectivity toward their target. This highlights the importance of
screening novel compounds for cancer therapy use. Along with this, screening pharmaceutically
established compounds for “off label” use against certain cancers is an area that is beginning to
experience growing interest. Developing methods for targeting multiple signaling networks
without interfering with heavily trafficked networks is now a major focus of cancer research
(Knight, 2010).

1.3 Hematologic Malignancies
Hematologic malignancies are cancers of the blood. The three major types of hematologic
malignancies include leukemia, lymphoma, and plasma cell neoplasms, the largest being leukemia.
Leukemia can be divided into two categories: lymphocytic or myeloid, depending on which blood
cells are impacted. The major disease categories for these diseases include B-, T- acute or chronic
lymphocytic leukemia (B-ALL and T-ALL), and acute or chronic myeloid leukemia (AML and
CML). According to the National Cancer Institute, an estimated 48,610 leukemia cases will be
diagnosed this year in the United States. These new cases will be an addition to the 287,963 people
6

already living with leukemia (Howlader, 2013). Such high numbers of leukemia cases give
credence to the importance of conducting cancer research aimed at improving treatment.
Importantly, developing cancer treatments that are selective in their targeting of cancer phenotypes
is greatly needed.
These cancers can arise from the bone marrow or from the lymphatic system in response to
internal triggers or environmental factors. While the innate immune system is designed to detect
and destroy abnormal cells, escape from natural killer (NK) cell surveillance is a main method of
hematologic malignancy. NK cells are part of the innate immune system and have anticancer
properties. Usually upon recognition of an abnormal cell, the NK cell has the ability to lyse the
abnormal cell, and prevent it from further differentiating into other cancerous cells. Avoidance of
NK cell surveillance is possible through rapid expansion of cancer cells, which is largely seen in
hematologic malignancies. NK cells are heavily researched today due to their potential roles as a
cancer therapy (Farnault, 2012).
The internal drivers of hematologic malignancies are the subject of innumerable
investigations. For example, the JAK family has been found to play central roles in the
development of certain types of leukemia (Scott, 2012). Mutations in key proteins, such as JAK2,
are seen in chronic myeloid leukemia and are involved in the mechanism by which the cells sustain
uncontrolled cellular proliferation. In addition to leukemia, JAK proteins have been found to serve
major roles in other hematological malignancies (Chen, 2012). Another cell survival pathway
frequently used by hematological malignancies includes mTOR, an intracellular serine/threonine
kinase that functions downstream of many pathways. One of the pathways that activate mTOR
includes the PI3K pathway, which leads to the modulation of the apoptosis pathway (Younes,
2011; Green, 2011).
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1.4 The Immune System
The ratio of microbes to human beings is overwhelmingly large. Every day the human body
fights off potentially dangerous microbes. Although this task seems cumbersome, it is
accomplished almost effortlessly by a sophisticated system. The human immune system is an
integrated network comprised of cells called leukocytes, collectively known as white blood cells
(WBCs). Two major divisions of WBCs exist and belong to either the lymphoid or myeloid
lineages. These lineages work together in order to maintain an effective immune response against
disease. Any imbalance in this system can lead to the human body being susceptible to pathogenic
threats. All WBCs are derived from pluripotent hematopoietic stem cells present in the bone
marrow. Through various stimuli, these pluripotent stem cells give rise to other types of stem cells
that are limited in their differentiating ability. These derivations of the pluripotent stem cells are
the lymphoid and myeloid progenitors. Unlike lymphoid progenitors, myeloid progenitors produce
cells that serve roles in other functions in addition to immune processes. Briefly, myeloid
progenitors give rise to megakaryocytes, erythroblasts, and granulocytes. These three divisions of
myeloid progenitors are involved in platelet and red blood cell formation, and immune responses,
respectively. The myeloid lineage gives emergence to many white blood cells that are vital for
innate immunity (Murphy, 2008).

1.4.1 The Myeloid Lineage
Currently the accepted model for hematopoiesis suggests that all blood cells are derived
from a single hematopoietic stem cell (HSC). Cytokines and growth factors present in the bone
marrow (BM) stimulate these HSCs allowing them to differentiate into two distinct lymphoid or
myeloid branches. Although the exact mechanisms of this process are debatable, new evidence
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highlights interconnecting signaling networks shared between HSC progenitors and mature
leukocytes. (Dorshkind, 2010),
On a daily basis, nearly 1-trillion blood cells arise in the BM. These cells are further
divided into their specialized roles, depending on the physiological requirements of the individual.
The specialized roles can range from immunity to oxygen transportation. Assigning such roles
depends on the chemical environment present within the BM and the hematopoietic stem cell’s
surface expression of certain receptors. The presence of such receptors dictates which lineage
(lymphoid or myeloid) the progenitor cells differentiate into. HSCs lose their differentiating ability
during their first division, giving rise to multipotent progenitors (MPPs). These MPPs can then be
stimulated to form either common myeloid progenitors (CMPs) or common lymphoid progenitors
(CLPs). CLPs give rise to T, B, and natural killer (NK) cells, which serve roles in memory (T and
B lymphocytes), and innate immune functions (NK cells). The CMP route is more complex, and
includes short lived cell types such as granulocytes, erythrocytes, and megakaryocytes (Doulatov,
2012; Iwasaki, 2007).
In the myeloid lineage cell surface markers such as lin-IL7Rα-Kit+Sca-1-CD34+FcγRlo,
dictate which MPPs will differentiate into CMPs. These progenitors can in turn give rise to
granulocyte-monocyte progenitors (GMPs), which are the primary producers of the myeloid
lineage (Friedman, 2007). As hematopoiesis is the term for the development of all blood cell types,
myelopoiesis is the term used to describe the formation of all myeloid lineage leukocytes. An
immense amount of signaling networks are involved throughout myelopoiesis, and the same
amount of signaling pathways are also present during the natural and abnormal functioning of the
myeloid leukocyte (Huber, 2012). Understanding the normal process of development that occurs
throughout hematopoiesis is crucial to investigating how cancers affecting the blood can arise.
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1.5 Chronic Myeloid Leukemia
Myeloid malignancies are clonal diseases of hematopoietic stem cells or their progenitors.
These malignancies have genetic alterations that allow for rapid self-renewal, proliferation, and
differentiation (Murati, 2012). Chronic myeloid leukemia is a myeloproliferative disease
characterized by clonal expansion of transformed, primitive hematopoietic progenitor cells (Faderl,
1999). Chronic myeloid leukemia (CML) has three different phases, which are the accelerated
(AP), chronic (CP), and blast phases (BP) (Scholar, 2007). Of these three phases, the blast phase is
least understood, and the prognosis in this phase is life expecting. A diagnosis of CML is made
when the Philadelphia chromosome is identified along with excessive immature granulocytes
present in the patients collected peripheral blood. The large majority of CML patients are
diagnosed during the chronic phase of the disease (Melo, 2007). Disease progression into advanced
stage CML (blast phase) is poorly understood and is frequently seen in CML patients who develop
resistance to cancer treatment. CML patients that enter blast crisis during the course of the disease
have a 20% survival rate (Radich, 2007).
Although there has been an extensive amount of research conducted on CML, more
research is needed to identify the underlying mechanisms of disease progression and to develop
better treatments for the advanced stages of CML.

1.5.1 BCR-ABL Signaling
In 1960, (Nowell et al.) a study consisting of seven chronic granulocytic leukemia (CGL)
patients provided results of a recurring minute chromosome, later named the Philadelphia (Ph)
chromosome. This study provided the first results of a consistent chromosomal abnormality
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associated with a specific type of leukemia, and was a major advancement for cancer research
(Deinger, 2000).
Thirteen years after identifying the Ph+ chromosome, a study involving nine CML patients
identified a translocation between the long arms of chromosome 9 and chromosome 22. This
translocation was concluded to be the primary cause of the Ph+ chromosome (Rowley, 1973). The
human cellular homologue (c-abl) of the Abelson (ABL) murine leukemia virus was found to be
the gene that was translocated in the Ph+ chromosome (de Klein, 1982). Studies involving CML
patients determined that the c-abl gene was specifically involved in Ph+ chromosome CML
patients (Bartram, 1983). At approximately the same time, another study by Groffen et al.,
identified a breakpoint domain present on chromosome 22 in 19 CML patients. This breakpoint
domain was then termed “breakpoint cluster region” (BCR). Half a decade later, further research
concluded that increased tyrosine kinase activity involving the Ph+ chromosome product protein,
BCR-ABL, was present in virtually every chronic myeloid leukemia patient (Daley, 1990; Lugo,
1990).
C-ABL (Figure 1.2a) has been found to be involved in cellular functions that govern
growth and differentiation. The protein c-ABL is ubiquitously expressed, and is normally found
migrating between the nucleus and cytosol. However, c-ABL remains confined to the cytosol when
it is fused with the BCR protein (Figure 1.2b). The exact mechanisms of the BCR protein by itself
are not yet fully understood, but like c-ABL, BCR is also ubiquitously expressed. ABL kinases
have been known to serve roles in other cancers, however, only in leukemia cancers is c-ABL
fused with BCR to form the constitutively active BCR-ABL protein (Figure 1.2c) (Greuber,
2013).
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A result of the BCR to ABL fusion is the constitutive activation of the ABL kinase protein.
Three different BCR-ABL proteins have been identified and include P210, P185, and P230. The
three proteins differ in the numbers of BCR coding sequences present in the fusion protein. P210
has been identified as the hallmark BCR-ABL protein form active in CML. BCR-ABL remains
active because BCR fusion prevents ABL kinase auto-inhibition capability (Greuber, 2013). This
constant activated state of BCR-ABL present in the cytosol leads to activation of other proteins
and ultimately to cytokine independence. The proteins that are frequently activated by BCR-ABL
also serve as important intermediates in pathways such as the Ras/Raf/Mek/Erk, PI3K/Akt, SFK,
SAPK, and JAK/STAT pathways (Figure 1.3). Adapter molecules such as Grb-2 can lead to
recruitment of Sos proteins, which are capable of activating Ras via utilization of GTP (Pendergast
AM, 1993). Other known substrates of BCR-ABL known to activate the Ras pathway are Shc and
CrkL. CrkL is a tyrosine kinase with SH domains that are capable of binding active and inactive
ABL proteins (Oda, 1994). JNK/SAPK signaling is also utilized by BCR-ABL signaling along
with the combinational use of the p38 protein. These pathways have been shown to serve
important roles in BCR-ABL’s transforming capabilities (Deininger, 2000). The exact mechanisms
of how BCR-ABL utilizes the Ras/Raf/Mek/Erk pathway are not fully understood.
The JAK/STAT pathway has also been found to be effected by BCR-ABL. BCR-ABLtransformed cell lines such as the K562 leukemia cells show constitutive activation of STAT5a/b
and STAT3 (de Groot, 1999). Other studies involving multiple cell lines have shown that STAT
proteins do not rely on JAK activation, but may be directly regulated by BCR-ABL. Along with
these findings studies have also shown that the activated JAK/STAT pathway in BCR-ABL
positive cells does not require IL-3 or GM-CSF for activation (Chai, 1997). Kabarowski et al.
showed that this growth factor independence may be due to BCR-ABL activation of Ras.
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Establishing multiple ways of sustaining cytokine independent cell growth is necessary for any
cancer, and is seen clearly in BCR-ABL signaling.
The PI3K pathway is a pathway that regulates apoptosis. In BCR-ABL positive cell lines,
increased BCR-ABL activity leads to elevated PI3K activity. This effect is mediated through Cbl
proteins along with the previously mentioned CrkL adapter proteins. A downstream target of the
PI3K pathway is the protein Bad, which is responsible for apoptosis initiation. In BCR-ABL
mutated cell lines, Bad has been shown to be inactive. Such results prompted Keeshan et al. to
investigate the effects of BCR-ABL on Bad functions. Their results showed that cells expressing
high levels of BCR-ABL were able to mimic IL-3 stimulation, and prevent Bad from performing
it’s apoptotic function (Deininger, 2000; Keeshan, 2002).

13

Figure 1.2 Structure of BCR-ABL Protein. a.) ABL Protein - SRC homology domains SH3
& SH2 are located near the NH2 terminus (Orange & Peach respectively). These domains
allow for interactions between other proteins. Linker region connects kinase domain (blue)
with SH2/SH3, and serves a role in regulating autophosphorylation. N-terminal cap NC
(white) with myristoylation (MYR) serves dual roles in membrane localization and kinase
activity. Near the 3’ end, nuclear localization signals, DNA-binding, and actin-binding motifs
are found (red and green respectively). b.) BCR Protein – A coiled-coiled domain is found at
the N-terminal end, which serves a role in dimer formation. Dimerization domain (DD, purple)
along with two cyclic adenosine monophosphate (cAMP) kinase homologous domains
(yellow) are utilized in Grb-2 binding, which plays a role in activating the Ras pathway. The
RHO-GEF center of the molecule is involved in Rho guanidine exchange factors, and acts in
activating transcription factors such as NF-κB. The c-terminus has a Rac molecule, which also
serves a purpose in activating the Ras pathway (Deininger, 2000). c.) BCR-ABL Protein – Myr
on ABL is replaced with BCR, causing fusion between BCR and ABL. The fusion of the
proteins causes a large portion of the N-cap region to be removed keeping regions of the BCR
and ABL proteins intact (Panjarlan, 2013).
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Figure 1.3 Constitutive activation of BCR-Abl influences activity of multiple pathways.
BCR-Abl is a constitutively activated tyrosine kinase with dual kinase activity that allows it
to modulate various signaling cascades within the cell.
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1.5.2 BCR-ABL Independent Pathways
Besides BCR-ABL, other mutations can lead to a CML phenotype. One particular
oncogenic mutation occurs in the fms-related tyrosine kinase 3 (FLT3) receptor. During blast crisis
in CML patients, FLT3 has been shown to be overexpressed. This mutation has been found to lead
to increased cellular proliferation by activating downstream signaling cascades such as the ones
already mentioned (Small, 2006; Weisberg, 2010) FLT3 mutations are heavily investigated for
their role in drug resistant CML and AML. Particularly in AML, FLT3 inhibition has shown to be
an effective way of stopping disease progression (Leung, 2013). The JAK2 V617F mutation is
another BCR-ABL independent pathway seen frequently in CML patients. This mutation results in
a loss of autoinhibitory function of JAK2 leading to increased activation. In patients with this
mutation, downstream targets such as STAT5 and STAT3 are found to be constitutively activated
(Staerk, 2012; Scott 2012). Another BCR-ABL independent pathway found in CML patients
involves the Tel-Platelet-derived Growth Factor Receptor β (Tel-PdgfR β). This pathway is rarely
seen in CML patients but deserves mentioning because of its ability to achieve constitutive
tyrosine phosphorylation. Knowledge of this pathway’s exact mechanisms in sustaining CML
disease is unknown, however, studies have shown Tel-PdgfR β to have influence on PI3K
signaling, and regulation of transcription (Huang, 2012).

1.5.3 Current Therapies in the Treatment of CML
Due to the discovery of Imatinib’s capability to inhibit BCR-ABL tyrosine kinase activity
through binding of the ATP pocket domain, CML treatment has forever changed. Prior to the
tyrosine kinase inhibitor era, the main treatment for CML was interferon therapy, and prior to that
was standard chemotherapy (busulfan and hydroxyurea). Interferon therapy works by targeting
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CML stem cells, but is mainly beneficial for patients in the early stages of the disease (Talpaz,
2013). Although tyrosine kinase inhibitors have shown promise in improving the prognosis of
CML patients, approximately one-third of CML patients will develop resistance to Imatinib
(Marin, 2013). Such incidences of drug resistance has prompted researchers to find new TKIs
capable of inhibiting these types of cancers.
Second generation TKIs such as Dasatinib (Sprycel, Bristol-Myers) and Nilotinib (Tasigna,
Novartis) were developed soon after the discovery of drug resistant CML patients. Drugs such as
Dasatinib have the ability to target multiple kinases at low concentrations and thus are considered
pan-kinase inhibitors. However, the full spectrum of TKI activity remains to be discovered, and is
being studied using methods that measure the activity of many different cellular pathways
simultaneously (Karaman, 2008; Rix, 2007).
Since 2001, more than 15 kinase inhibitors have been approved by the FDA for treatment
of various cancers. One persistent problem is that many cancer patients do not respond to second
generation TKIs. Patients, who have exhausted all options of cancer treatment, usually end up
receiving hematopoietic stem cell transplantation. Although transplantation is a cure for CML, the
problem of finding matching donors for CML patients is a significant limiting factor (Pavlu, 2011).
In addition to treating CML with these small molecule inhibitors, they also show promise
in selectively treating other cancers. The importance of identifying enzymes, such as kinases,
that serve active roles within various drug resistant cancer signaling networks, along with
identifying genetic aberrations that drive the malfunctioning of such proteins, makes this
research a priority.
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Chapter II: Signaling Networks within Myeloid Cells
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In order to understand the mechanism by which BCR-Abl is capable of sustaining cytokine
independent growth, a brief overview of the common signaling pathways within myeloid cells is
necessary.

2.1 JAK-STAT Pathway
During a normal physiological state, myeloid and monocyte differentiation is governed by
hematopoietic cytokines. Janus tyrosine kinases (JAKs) and signal transducers and activators of
transcription (STATs) are proteins intricately involved in cytokine stimulated intracellular
signaling (Liu, 1998).
To date, seven STAT proteins have been identified, STAT1, STAT2, STAT3, STAT4,
STAT5a, STAT5b, and STAT6. Along with the STAT proteins, four members of the JAK family
(JAK1, JAK2, JAK3, and Tyk2) have also been discovered (Leonard, 1998).
JAKs have seven JAK homology (JH) domains (JH1-JH7). Each domain has its
own unique role in the catalytic activity of the protein. STATs also have special domains present
within their protein structure that dictate their interactions with other intracellular signaling
networks. For example, each STAT molecule contains six domains that are required for the
transactivation and DNA binding property of the protein. (Ross, 2007). Stability of such domains
is required for the proper functioning of the cell. For example, mutations within the transactivation
domain of STAT5a can lead to increased activation. Gu et al demonstrated that the amino acid
variant phenylalanine replacing serine at amino acid position 710 promotes migration and invasion
of prostate cancer cells, which is a prerequisite for metastases.
Cytokine initiated JAK/STAT signaling pathways are orchestrated through various
cytokine receptors. Each receptor activates a specific set of JAKs and STATs, and does so through
the previously described domains that are present in these proteins (JH domains of JAKs; SH2 and
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other domains of STATS). Receptors associated with activating JAK proteins are the interferon
(IFN) and interleukin (IL) receptors. The cytokine activated cascade in the JAK/STAT pathway
begins with the docking of a cytokine (interferon or interleukin) to its respective receptor (Figure
2.1). Docking of the cytokine then leads to dimerization of the two receptors while simultaneously
recruiting JAK proteins to the cytoplasmic domains of the receptors (Kirken, 1994; Ihle 1997).
Instantaneously, when the two receptors dimerize, the receptor bound JAK proteins
autophosphorylate each other. Once phosphorylated, STAT docking sites are formed on the
surface of the interleukin receptors. In close proximity, STAT proteins interact with the
phosphorylated JAK proteins via their SH2 domain, and then become phosphorylated. After the
STAT proteins are phosphorylated they form dimers with other phosphorylated STAT proteins
present in the cytoplasm. The activated STATs translocate to the nucleus of the cell where they
interact with specific binding sites present on DNA. The nuclear activity of dimerized STAT
proteins subsequently leads to gene transcription within the cell (Levy, 2002; Schindler, 2007).
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Figure 2.1 Schematic representation of the JAK/STAT pathway. Cytokine/growth factor
docking to it’s respective receptor is essential for the activation of the pathway. Different
cytokines/growth factors (IL-2, IL-3, and G-CSF) recruit JAK proteins, and lead to the
activation of Stat proteins. Activated Stat proteins then translocate to the nucleus and bind
DNA sites to activate transcription.

21

Within neutrophilic and granulocytic precursor cells, the JAK/STAT pathway is utilized in
cell development. Granulocyte colony-stimulating factor (G-CSF) regulates the proliferation and
differentiation of neutrophilic-granulocyte precursor cells present in the bone marrow. G-CSF
receptors share similarities with interleukin recepters. Tian et al. showed that STAT3 and STAT5
are utilized in G-CSF initiated signaling. Other studies have shown STAT3 and STAT5 have roles
in controlling myeloid differentiation through other receptor systems such as signal transducing
subunit gp130 and erythropoietin receptor signaling. The latter system is primarily involved in
erythroid cell differentiation. In addition to cell development, STAT5 also serves an important role
in myeloid cell survival (Smithgall, 2000).

2.2 Src Family Kinases (SFKs)
Src proteins were the first type of protein kinases to be discovered that showed
phosphorylation at tyrosine residues, giving rise to a new division of protein kinases. Src proteins
contain regions of homology that have been coined Src homology (SH) domains. Along with these
SH domains, Src proteins also contain a catalytic domain where the activating tyrosine residue
resides (Martin, 2001).
SFKs include the Src, Lyn, Fyn, Yes, Fgr, Hck, Blk, Zap-707, and Yrk non-receptor
protein tyrosine kinases that respond to various stimuli including growth factors, cytokines, and
steroids. SFKs remain in close proximity or bound to the plasma membrane of the cell. Fgr and
Hck kinases are the major SFKs expressed within myeloid cells. Hck inhibits expansion of the
myeloid progenitor pool, and works with Fgr to promote survival and function of differentiated
myeloid cells. SFK may control functions that govern cytoskeleton rearrangement, cell motility,
cell adhesion, translation, metabolism, proliferation, and cell survival within myeloid cells (Huber,
2012).
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Activation of SFKs is carried out by receptor tyrosine kinases (RTKs) or G-protein-coupled
receptors (GPCRs). Once SFKs are activated they can initiate various signaling cascades (Figure
2.2). In myeloid cells, SFK can initiate phosphorylation of STAT proteins, specifically STAT3.
Along with direct activation of certain proteins, SFKs initiate activation of Ras/Raf/MEK/ERK,
PI3K/AKT, and PKC signaling cascades (Miranda, 2007). SFKs are involved in many processes,
and are ubiquitously expressed in many cell types. As you will see later, SFKs also play vital roles
in cancer progression.
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Figure 2.2 Src Family Kinases (SFKs) Signaling Networks. SFK regulate multiple
pathways. SFKs (blue colored proteins) activate pathways that lead to cell survival, gene
transcription, and protein degradation. In this figure SFKs interact with PKC signaling to
initiate protein degradation via proteasomes. SFKs are also depicted interacting with
STAT signaling and the Raf/MEK/ERK pathway to activate transcription. SFKs also
interact with PI3K networks to regulate apoptosis.
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2.3 Ras Signaling
The Rat sarcoma protein (Ras) family consists of a large number of similar structured
GTPase proteins that are bound to the plasma membrane of the cell. The primary Ras GTPase
proteins are the H-, K-, N-, E-, R-, and M-Ras proteins and are activated by mitogens, cytokines,
and growth factors. Ras proteins function in cellular proliferation and cell cycle progression
through transcription, translation, and degradation of key cell-cycle components (Figure 2.3). In
human hematopoietic cells, progenitor cells of the myeloid lineage rely largely on the activity of
H-Ras (Huber, 2013).
The mammalian cell cycle consists of four phases: the first gap phase (G1 phase), the DNA
synthesis phase (S phase), the second gap phase (G2 phase), and mitosis (M phase). Transition
between phases is policed in part by cyclin-dependent kinases (CDKs) along with their regulatory
subunits, cyclins throughout Ras signaling. Two major cyclin subunits are involved in the Ras
signaling network, D- and E-type cyclins. Each cyclin has it’s own unique feature on it’s
respective CDK. These features can range from activation to inhibition of other proteins. A major
downstream target of Ras GTPases is the MAPK signaling cascade, which includes RAF, MEK,
MAPK, and ERK proteins. Through the latter pathway, GTP bound Ras is able to regulate G1through S-phase cell cycle progression. One major function for Ras proteins is the inhibition of the
retinoblastoma protein (RB) through the activation of the RAF-MEK-ERK/MAPK pathway. RB is
an important growth suppressing protein, and inhibiting it’s activity can lead to cellular
proliferation and increase the likelihood of cancer. Other targets of Ras proteins include
phosphatidylinositol 3-kinases in which cellular apoptosis can be regulated. Finally, Ras proteins
can also target a family of GTPases that contribute largely to cell-cycle progression, RAL proteins.
(Coleman, 2004).
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Figure 2.3 Ras Signaling Pathway. Ras carries out its GTP initiated activity at the cell
membrane. Four different paths can lead to cell cycle arrest at different phases of the cell
cycle. For example, Ras can activate p16 which can then activate a downstream target INK4
which prevents INK4 from activating CDK and RB, ultimately leading to G1 phase arrest.
Another route includes inhibiting MDM2 which leads to the accumulation of p53 within the
cell, and eventually to cell cycle arrest.
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2.4 Raf/MEK/ERK Pathway
As mentioned previously, the Raf/MEK/ERK pathway is an important downstream
signaling cascade that is targeted by RAS GTPase proteins. The Raf family is composed of three
members: A-Raf, B-Raf, and C-Raf. Each isoform contains three conserved regions: CR1, CR2,
and CR3. These three regions serve roles in Ras-binding, apoptosis regulation, and kinase activity
respectively (Figure 2.4). Mutations within Raf proteins, such as the V600E B-Raf mutant, have
contributed to the prevalence of many cancers, the most common being melanoma (Sun, 2014).
Although the Raf proteins are major targets for the Ras GTPase protein, they do not require Ras to
be activated. However, Ras proteins do recruit Raf proteins towards the cellular membrane, and
allow Raf to interact with other proteins along the way. Mitogen-activated protein kinase/ERK
kinase proteins (MEK) are the downstream targets for Raf proteins. MEK proteins are part of the
larger family of mitogen-activated protein kinases (MAPK) that are major players in pathways that
regulate embryogenesis, cell differentiation, proliferation, and death. MEK proteins are also
capable of phosphorylating serine/threonine and tyrosine residues, making them dual specificity
kinases (Pearson, 2001).
The MEK family consists of five different proteins: MEK1, MEK2, MEK3, MEK4, and
MEK5. In myelopoiesis, MEK1/2 are the primary acting MEK proteins. Currently the only known
substrates for MEK are the four members of the extracellular signal-related kinase (ERK) family:
ERK 1/2, JNK 1/2/3, p38 MAPK, and ERK5. MEK1/2 proteins primarily interact and activate
ERK1/2 proteins, which in turn transition into the nucleus to initiate proliferative signals.
Interleukin 3 (IL-3), G-CSF, and granulocyte macrophage colony-stimulating factor (GM-CSF) are
all initiators of the RAF/MEK/ERK pathway in myeloid lineage cells (Chung, 2011).
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Figure 2.4 Raf/MEK/ERK Pathway. This pathway is activated by proteins from other
pathways such as Akt (PI3K Signaling), PKCs , and SFKs. This pathway also utilizes other
pathway substrates, such as STAT proteins to regulate cell differentiation.
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2.5 P38 MAPK and JNK/SAPK
Four genes encode p38 MAPKs: MAPK11, MAPK12, MAPK13, and MAPK14. Jun Nterminal kinase (JNK) proteins are encoded by three genes: MAPK8, MAPK9, and MAPK10,
which are translated to JNK1, JNK2, and JNK3 respectively. JNK proteins and p38 MAPKs
function in response to environmental and genotoxic stresses (Figure 2.5). Along with these
functions, the two interact at with one another to control cell proliferation, differentiation, and cell
survival (Wagner, 2009).
In myeloid cells, TGFβ and interferon binding to their respective receptors leads to
activation of the MAPK pathway. These activated receptors carry out their functions internally
through utilization of proteins such as G-proteins, myosin light chain kinases (MLKs), and the p21
protein. This pathway has positive and negative regulatory effects. Positive regulation includes p38
MAPK activation of C/EBPε, which then leads to C/EBPε binding to DNA and sequentially
initiates cellular differentiation. In myeloid cells, this process is responsible for early multi-lineage
differentiation of myeloid cells. Interestingly, this same pathway can also lead to cellular growth
suppression, depending on the growth factor/cytokine that initiated the signaling cascade. JNK to
SAPK signaling acts as a negative regulatory mechanism of this pathway. In this pathway, JNK
and SAPK are activated by phosphorylated MKK 4/7 or activated cytokine receptors. IL-3 and GCSF are the known growth factors involved in JNK to SAPK signaling. After JNK/SAPK has been
activated, the signaling cascade triggers the release of cytochrome c from the mitochondria leading
to apoptosis (Miranda, 2007).
Other studies have shown JNK to be activated by Hematopoietic Progenitor Kinase 1
(HPK1) protein. Such activation has been demonstrated to lead to cell survival and differentiation.
To date, limited information is available to what other factors stimulate JNK (Huber, 2012).
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Figure 2.5 P38 MAPK and JNK/SAPK Pathway. This pathway is unique in that there are
two different results of it’s functioning, differentiation or growth suppression. Through p38
MAPK, the pathway can result in growth suppression or cellular differentiation. JNK/SAPK
signaling can also lead to cell apoptosis through the release of cytochrome C from the
mitochondria.
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2.6 PI3K Signaling
PI3K is a lipid kinase protein that is involved in a multitude of intracellular signaling
pathways (Figure 2.6). The PI3K family consists of three PI3K subclasses, and class I PI3K
proteins have been shown to play major roles in cellular differentiation, glucose uptake, vesicular
trafficking, and apoptosis within myeloid cells (Yao, 1995).
PI3K class I proteins have three different catalytic classes p110α, p110β, and p110δ. These
proteins are activated by specific kinases and form heterodimers with adapter molecules such as
p85α, p85β, p50α, p55α, and p55γ (Polak, 2012). For simplicity, instead of listing each class and
subclass present within a signaling cascade, we will refer to the term PI3K to collectively represent
these classes. PI3K is also known to regulate cellular differentiation, glucose uptake, vesicular
trafficking, and apoptosis through signaling cascades initiated by tyrosine residue phosphorylation
on selected proteins (Kapeller, 1994).
As mentioned earlier, G-CSF is involved in granulocyte differentiation and proliferation.
Studies have shown G-CSFR recruits PI3K to the specific domains on the receptor. Such
recruitment of PI3K has been proven to lead to inhibited apoptosis, and enhanced proliferation
(Hunter, 1998). Normal physiology of monocyte and granulocytes rely heavily on PI3K signaling.
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Figure 2.6 PI3K Signaling Pathway. PI3K signaling is a well-integrated pathway with
connections to almost every other signaling network. Cells of the myeloid lineage utilize this
pathway mainly for functions involving apoptosis and cell survival. SFKs, MEK1/2, Grb,
Cbl, and PIP3 are all capable of activating PI3K (Note in this figure that PIP3 is a membrane
bound protein. One of the two PIP3 proteins shown, is not attached to the cell membrane for
clarity of highlighting the flow of the pathway). In most cases, PI3K activates PIP3, which
then leads to activation of Akt. After Akt is activated, multiple downstream apoptosis proteins
such as the caspases are deactivated.
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2.7 TGFβ/SMAD Pathway
Transforming growth factor beta (TGFβ) and small body size mothers against
decapentaplegic (SMAD) proteins are regulators of cellular transcription through their respective
serine/threonine receptor kinases (TGFβR) (Figure 2.7). The binding of TGFβ to it’s tyrosine
receptor kinase can lead to the internal activation of SMAD proteins through serine/threonine
activity. Depending on the receptor activated, different SMAD proteins will respond. SMAD
protein homologs SMAD-1, -2, -3, -5, and -8 have been shown to target and activate downstream
SMAD-4 which ultimately leads to gene transcription, and cellular differentiation. On the other
end, SMAD-6 and -7 have been shown to activate p21 protein which then leads to growth
suppression of the cell. Besides having several roles in myeloid differentiation, this pathway is also
actively involved in various blood cell lines (Miranda, 2007).
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Figure 2.7 TGFβ/SMAD Pathway. This pathway utilizes receptor tyrosine kinases to initiate
the signaling cascade. The effects of the signaling cascade can be either negative or positive
depending on which Smad proteins are activated during the process.
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2.8 Protein Kinase C (PKC)
The protein kinase C (PKC) family consists of 12 serine/threonine kinases that serve roles
in cell proliferation, differentiation, apoptosis, and angiogenesis. PKCs are calcium dependent and
are activated by both phophotidylserine (PS) and diacylglycerol (DAG). Recent studies have
shown that PI3K pathways, and phospholipase C (PLC) can also indirectly activate PKCs (Figure
2.8). Little is known about PKC signaling, but to date, the MEK-ERK pathway is known to serve
an important role in PKC signaling (Mackay, 2007).
In primary granulo-monocytic progenitors, PKCs serve major roles in lineage commitment.
Along with this mechanism, some PKCs, such as PKCδ are phosphorylated by SFKs. Signaling
networks involving PKCs are diverse, and information regarding the exact mechanisms of such
pathways is limited. However, studies continue to elucidate the potential roles PKCs serve as
therapeutic targets in various malignancies based on their interactions with other signaling
networks (Miranda, 2007).
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Figure 2.8 Protein Kinase C (PKC) Signaling Pathway. PKC is capable of being activated
by either GPCRs, NRTKs, and RTKs. Myeloid cells ability to differentiate relies heavily on
PKC functioning. PKCs carry out their activity at the cytosolic side of the plasma membrane,
where they interact with GPCRs and other receptors. PKCs can also initiate a looping network
by activating Phospholipase C (PLC), which leads to increased production of DAG, and
ultimately increased activation of PKC by DAG.
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Figure 2.9 Crosstalk between pathways within myeloid cells. All pathways are connected
between one another through one or more intermediates. This feature is important in
understanding cell signaling.
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2.9 Hypothesis and Significance
All the signaling cascades described above (Figure 2.9) allow for cells within the myeloid
lineage to perform their everyday functions within the innate immune system. Mutations can arise
within the genome of these cells resulting in severe changes with protein function and normal
signal transduction. Such alterations can lead to aberrant activation or function of the
aforementioned pathways ultimately resulting in malignancy or immune dysfunction.
Modern cancer drugs are designed with the intent to selectively inhibit specific pathways.
Although cancer deaths have dramatically decreased within the developed world, the number of
drug resistant forms of cancer continues to rise. Additionally, many underrepresented minorities,
and citizens of developing countries suffer from high cancer mortality rates. Discovering methods
that will allow for clinical detection of a patient’s likelihood of developing drug resistance is of
extreme importance. Also, identifying compounds that are capable of reversing drug resistance are
of great benefit for the cancer patient.
Chronic myeloid leukemia has served as a model for how cancer can be selectively targeted
by special small molecule inhibitors, and has brought an entire new meaning to personalized
medicine. Since 2001, the survival rates of chronic myeloid leukemia have decreased significantly,
but mortality rates have continued to remain a problem within the El Paso County area (Figure
2.10). Besides serving as a model for personalized medicine, CML has also served as a model for
drug resistance. Since the installation of imatinib in treating CML many cases of drug resistant
CML have arose. Such cases have illuminated how cancers can acquire drug resistance over time.
It is therefore important that we continue to utilize CML as a model to further explore the genomic
and proteomic landscape of drug resistance within cancer.
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Figure 2.10 CML Mortality Rates in Texas. Between 2000 and 2010, El Paso had
one of the highest mortality rates due to CML. (Texas Department of State Health
Services, 2014).

The main objective of this research was to test the hypothesis that artificially generated
imatinib resistant tumor cell lines can reveal intra and inter oncogenic drivers as novel
therapeutic targets in the treatment of CML. With this hypothesis our main research goal
was to identify multiple ways that BCR-ABL signaling in drug resistant CML can be
exploited using small molecule inhibitors.
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Chapter III: Activated Pathways that are Secondary to Treatment by Small
Molecule Inhibitors
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3.1 Introduction
There exist a multitude of mutations within the BCR-Abl protein that gives rise to drug
resistant CML. Of these, the T315I mutation is the most common, and one of the most drug
resistant mutants (Figure 3.1).

Figure 3.1 Incidence of mutations in clinical practice. All BCR-Abl mutations
within CML that have been reported. (p: P-loop/ATP binding site; b: imatinib
binding site; c: catalytic site; a: activation site), (Apperley, 2007).

Mutations differ from one another depending on which residue within the protein they
impact. For example, the four most common BCR-Abl mutations occur within the ATP-binding,
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imatinib binding, catalytic, or activating domains of the protein (highlighted in green in Figure 14.)
The T315I mutation occurs within the Imatinib binding pocket (Figure 3.2), and results in a
threonine to isoleucine variant. The threonine amino acid contains a hydroxyl group that is
necessary for imatinib attachment. Without threonine present, imatinib along with other kinase
inhibitors are unable to bind properly and perform their inhibitory actions on the T315I mutant.
Many CML studies have been aimed at designing small molecules that selectively inhibit BCRAbl mutants. Second generation TKIs such as Nilotinib and Dasatinib have shown high selectivity
for various SFK proteins, and have shown even greater response towards the majority of BCR-Abl
drug resistant mutants.
However, the T315I mutant is resistant to second generation TKIs. Third generation TKIs
such as Ponatinib have emerged on to the scene in treating T315I mutant CML cases, and have had
success. As of 2013, Ponatinib was recalled by the FDA due to its adverse side effects largely seen
within patients administered the medication. Overcoming such negative side effects in drug
development remains an obstacle for advancing targeted cancer therapy. One fact to keep in mind
is that TKIs have only been in clinical use for less than two decades. Hence, this field of cancer
therapy development is still in its early years.
To investigate our hypothesis, we developed an artificially generated imatinib resistant cell
line from an established cell line, KCL-22. The KCL-22 cell line is originally a human chronic
myeloid leukemia in blast crisis. The cell line was established from the pleural effusion of a 32year old woman with Philadelphia chromosome-positive CML in blast crisis; described to contain
the t(9;22) b2-a2 fusion gene and a p53 mutation (Kuonishi, 1983;Drexler, 1999).
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Figure 3.2 Imatinib Mechanism of BCR-Abl Inhibition. Imatinib, like other
tyrosine kinase inhibitors is an ATP competitive inhibitor. Imatinib binds to the
ATP pocket and prevents phosphorylation of the enzymes substrate.
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3.2 Materials and Methods
3.2.1 Cell Culture: The CML blast crisis cell line KCL-22, K562, and YT cell lines were
maintained using RPMI 1640 1x media (HyClone, UT) containing 1% Penicillin/Streptomycin
(Corning, VA), 1% L-Glutamine (Corning, VA), and 10% heat inactivated fetal calf serum
(Atlanta Biologicals, GA) as reported previously (Nagy, 2009). Incubation conditions of cells
were at 37 °C in humidified 5% carbon dioxide (CO2) atmosphere, in a regular water jacketed
incubator.

3.2.2 Establish imatinib resistant cell model: Cells were kept in culture with imatinib
concentrations of 500 nM, 750 nM, and 1 μM during weeks 1-2, weeks 3-4, and weeks 4-6
respectively. During these six weeks, cells were passaged at 40% of the standing population every
three days. Cell population density was consistently maintained between 5-10 million cells in a
T75 flask.

3.2.3 Drug Concentrations: Imatinib and other kinase inhibitor concentration dose curves were
obtained from literature regarding phase I evaluations of each drug. Literature provided peak
concentrations (Cmax) values for each drug. Peak Concentrations for FDA approved drugs used in
primary dose curves were as follows: Imatinib (4,478.0 ng/ml) (Peng et al., 2004), Gefitinib
(443.88 ng/ml) (Milton et al., 2007), Dasatinib (46 ng/ml) (Demetri et al., 2009), Sunitinib (70.9
ng/ul) (Faiyre et al., 2006), Erlotinib (1,737 ng/ul) (Hidalgo et al., 2001), Lapatinib (2470 ng/ul)
(Chu et al., 2008), Nilotinib (3.6 uM) (DeRemer et al., 2008), Sorafenib (2,248 ng/ul) (Strumberg
et al., 2005), Trametinib (33.4ng/mL) (Infante et al., 2012), and Vemurafenib (61μg/mL) (Grippo
et al., 2013).

44

3.2.4 Luminex Analysis: Phosphorylation activity and protein expression were analyzed utilizing
Luminex 100/200 System, Austin, TX. Milliplex panels were obtained from Millipore, Billerica,
MA, USA. Panels used included: SFK Panel (Blk:Tyr389, Fgr:Tyr412, Fyn:Tyr420, Hck:Tyr411,
Lck:Tyr394, Src:Tyr419, Yes:Tyr412), RTK Panel (Pan Tyr), 9-Plex MultiPathway Panel,
Apoptosis (Caspase3:Active, GAPDH:Total, PARP:Cleaved), STAT Panel(STAT1:Tyr701,
STAT2:Tyr690, STAT3:Tyr705, STAT5A/B:Tyr694/699, STAT6 (Tyr641), BCR-ABL Panel
(BioRad Laboratores), and Early Apoptosis Panels Panel (Akt:Ser473, BAD:Ser112, Bcl-2:Ser70,
Active Caspase 8:Total, Active Caspase 9:Total, JNK:Thr183/185, p53:Ser46) were used.
Manufacture protocol was followed for each panel.

3.2.5 Proliferation Assays: Cells were cultured in complete media (previously described, Ross
2007) with Cmax concentration of respective drug. Cells were seeded at a concentration of 1.0 x
104 cells per well in a 96-well plate. Plate was kept in incubation for 72-hours. After 72-hours,
CellTiter96 MTS Reagent Promega was used, and manufacture protocol was followed. Plates were
read using a plate reader set to wavelength of 490 nm.

3.2.6 Cell Cloning: KCL-22 cells were cloned using serial dilutions in a 96-well plate. Cells were
cultured in imatinib (Cmax concentration) containing media. After 1.0 x 107 cells arose from one
clone, a sub-cloning process was performed. Cells were placed into expanded culture after
population grew to 1.0 x 107 cells a second time.
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3.2.7 PBMC Stimulation: Normal PBMCs were stimulated using phytohaemagglutinin (PHA).
Cells were kept in culture with PHA for 72-hours in complete media.

3.2.8 Statistical Analysis of Protein Activation: Statistics employed were performed utilizing
Minitab Statistical Software and SAS Statistical software. Statistics consultation was obtained with
Dr. Julia Bader, Research Specialist UTEP Mathematical Sciences.

3.2.9 Cell Staining: Phosphorylated JAK3 Tyr980 (sc-16567), JAK3 B-12 (sc-6932), and STAT5
C-17 sc-835 antibodies were obtained from Santa Cruz Biotechnology, and were used at a dilution
1:250 in Tween-PBS. Phosphorylated ERK1/2 Thr202/Tyr204 (9101), Phosphorylated C-Raf
Ser338 (9427) and Phosphorylated STAT5 Tyr694 (9427) antibodies were obtained from Santa
Cruz Biotechnology, and were used at a dilution 1:250 in Tween-PBS. Cells were left in primary
antibody over night, washed with Tween-PBS, and were stained with respective Cy2 or Cy3
secondary (dilution 1:400) and DAPI (1:800) for one hour.

3.2.10 Immunofluorescent Confocal Microscopy: Cells were adherent, and were cultured on sterile
cover slips inside a six-well culture plate, containing complete RPMI media. The cells were
visualized using a Zeiss LSM 700 confocal microscope using a 40× oil immersion objective (Carl
Zeiss) in the multitrack scanning mode with excitation wavelengths set at 488 (argon laser), 543,
and 633 nm (He-Ne lasers); emission wavelengths were 505–530 nm and >560 nm for detection of
the Cy2 and Cy3 coupled secondary antibodies, respectively. Images were captured using the ZEN
2009 (version 5.5) software and exported in a 12-bit TIFF RGB format to Adobe Photoshop and
Illustrator CS4 for processing.
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3.3 Results
3.3.1 Generation of Imatinib Resistant KCL-22 Cell Line
KCL-22WT cells were placed in imatinib containing culture, and viable cells were selected
for. After six weeks of increasing concentrations of imatinib, KCL-22 cells displayed insensitivity
towards Cmax concentrations of imatinib in comparison to KCL-22WT cells. Initially, KCL-22
cells showed an IC50 with imatinib less than 1 μM, and an IC50 with dasatinib less than 10 nM.
After KCL-22 cells were desensitized to imatinib over six weeks, KCL-22 cells displayed IC50
values to imatinib and dasatinib at >10μM. KCL-22IR cells were then placed into imatinib free
culture for four weeks in order to eliminate the possibility of imatinib insensitivity being caused by
increased cellular metabolism of drug. Imatinib insensitivity remained after imatinib withdrawal
period of four weeks. After demonstrating that KCL-22 cells were now insensitive to imatinib,
cloning of KCL-22IR cells was performed as described in methods. This was done in order to
acquire a homogenous population of KCL-22 resistant cells. At the end of the cloning process,
approximately eight weeks, KCL-22IR cells no longer displayed an IC50 value with Cmax
concentrations of Dasatinib, and cell % viability did not fall below 90% with Cmax concentrations
of imatinib (Figure 3.3a).

47

b.)
Cellular Pathways Analyzed

Targets

Apoptosis

GAPDH, Active Caspase 3, Cleaved
PARP
JNK, Bad, Bcl-2, Akt, Caspase 9, p53,

Early Apoptosis

Caspase 8
BCR-Abl

Phospho and Total BCR-Abl

Receptor Tyrosine Kinases

VEGFR1, VEGFR2, c-Kit, VEGFR3,
MCSFR, TIE2, TIE1, PDGFRb, FLT3,
PDGFRa

Src Family Kinases

Src, Fyn, Yes, Lck, Lyn, Fgr, Blk, Hck

MAPK/transcription- Pathways

CREB, NFKb, p38, ERK1/2, p70S6k,

JAK3/Raf/Shc/PI3K/Receptor Protein- Pathways

Shc, JAK3, Raf-1, PLCy, Tec, Itk, PI3k,
LAT, Zap70
STAT2, STAT1, STAT3, STAT5,

STAT Pathway

STAT6
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Figure 3.3 KCL-22 Cells Become Insensitive to Imatinib. aI.) WT KCL-22 Cell line was
treated with two TKIs (Dasatinib & Imatinib). The WT KCL-22 cell line is sensitive to Dasatinib
and Imatinib with IC50 concentrations of ~<10 nM and ~<1 μM, respectively. aII.) After culturing
KCL-22 cells in imatinib, KCL-22 cells became insensitive at significant clinical concentrations and
showed a significant increase in insensitivity towards Dasatinib. Imatinib did not reveal any IC50
concentration, and only presented an IC20 concentration at 10 μM. Dasatinib displayed an IC50
concentration of 1 μM. aIII.). After cells were cloned and grown in 10 μM of Imatinib, cells showed
almost 100% insensitivity to Imatinib, and no longer displayed an IC50 with Dasatinib. An IC30
concentration is seen with Dasatinib at 1 μM. These results compliment Imatinib and Dasatinib’s
inefficacy at inhibiting ATP activity, seen in highly drug resistant CML patients. N=3. b.) List of
pathways analyzed utilizing Luminex. Ras/Raf/MEK/ERK, JAK/STAT, Akt/PI3K, Apoptosis, RTK
Signaling, SFK, Protein Kinase signaling pathways are represented by one or several targets
analyzed.

3.3.2 Identification of Activated Pathways in Response to Imatinib Resistance
To identify potential compensatory pathways that are activated secondary to small
molecule inhibitors KCL-22IR cells were analyzed for changes in protein activation. Forty-eight
proteins were analyzed utilizing Luminex technology (Figure 3.3b). SFK phosphorylation levels
between KCL-22WT and KCL-22IR were markedly similar; however there were gradually
increased phosphorylation activity seen with LYN and FYN proteins in KCL-22IR cells. Mildly
decreased activity in LCK was also noted in KCL-22IR cells (Figure 3.4a).
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Figure 3.4 KCL-22IR vs WT KCL-22 Pathway Activation Profile. a.) KCL-WT and KCL-IR
SFK phosphorylation levels were measured using Luminex technology. Graph shows Mean
Fluorescent Intensity which indicates significance of phosphorylated state. Cells were compared
against five controls. Three controls were provided by the SFK Panel Manufacturer (HeLa
Unstimulated, HeLa Pervanadate, and Ramos Pervanadate). Two other controls used were normal
PBMCs and PHA activated PBMCs. Both KCL-22 cell types showed increased LYN activity in
comparison to controls. N=2. b.) Various pathways are represented in comparison to YT negative and
YT IL-2 stimulated cells. c.) Various pathways (MAPK, STAT, RTK, RPK, Apoptosis) are
represented including BCR-Abl activity. N=2.
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In comparison to WT KCL-22 cells, KCL-22IR cells demonstrated decreased Shc and Raf
activity. However, there was significant phosophorylation increases seen in JAK3, Itk, and Zap70
proteins (Figure 3.4b).
Figure 3.4c shows final comparison of phosphorylation levels between KCL22-IR and
KCL22-WT cells. Phosphorylated BCR-Abl was shown to be markedly decreased within IR cells,
however total protein expression of BCR-Abl was almost identical for both IR and WT cells. Also
noted was increased activation of Caspase 9 seen in IR cells. There were extremely significant
differences in ERK1/2 activation with IR cells showing nearly a 10-fold increase in activation
compared to WT KCL-22 cells. Interestingly there was also decreased activation of CREB and
STAT5 seen with IR cells in comparison to WT cells. RTK activity was measured and was
demonstrated that neither WT nor IR cells contain significant activation of RTK activity. These
findings suggest that cellular proliferation is being driven by an internal mechanism such as BCRAbl activity (Figure 3.4c).
Visualized in cell staining, we were able to observe expression of both JAK3 and STAT5
in both WT and IR KCL-22 cells. STAT5 appears to be more nuclear within the WT cells (Figure
3.5a), and more cytoplasmic within the IR cells. Phosphorylated states of JAK3 and STAT5 were
also confirmed (Figure 3.5b). Phosphorylated STAT5 appears to be more nuclear within the WT
cells, and more cytoplasmic within the IR cells, as confirmed by total antibody staining shown in
Figure 3.5a. Increased phosphorylated ERK1/2 levels were also noted in the IR cells (Figure3.5c),
whereas the WT cells demonstrated increased phosphorylated C-Raf (Figure3.5d). These results
confirm the findings noted in the multipathway analysis present in Figure 3.4.
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a.)

b.)
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c.)

d.)
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Figure 3.5 Immunofluorescent Staining of KCL-22IR/WT cells. a.) Total JAK3 (red
channel) and total STAT5 (green channel) are shown with nuclear staining (blue channel). b.)
Phosphorylated- JAK3 (red channel) and STAT5 (green channel) are shown with nuclear
staining (blue channel). Overall intensity of activated JAK3 is seen increased in KCL22-IR
cells. c.) Phosphorylated ERK1/2 is shown (green channel) with nuclear staining (blue
channel), overall intensity of active ERK1/2 is increased in KCL22-IR cells. d.)
Phosphorylated C-Raf is shown (green channel) with nuclear staining (blue channel), overall
C-Raf intensity is seen increased in KCL-22WT cells.

3.4 Discussion
In order for cells to function properly they must be able to maintain a homeostatic balance
when encountered with an environmental stress. Possessing such functions allows for cancer cells
to circumvent cell death caused by small molecule inhibitors. As demonstrated in our results,
various proteins expressed altered states of activation in response to imatinib insensitivity.
Noteworthy is the decreased active state of BCR-Abl within the KCL-22 imatinib resistant
daughter cells. Theoretically, a CML possessing such insensitivity as seen within our IR generated
cell line would be problematic to treat inside a clinical setting. Rationally, one would think that if
KCL-22IR cells were not responsive to BCR-Abl selective drugs, then they would possess higher
levels of BCR-Abl activation. This rationalization is contradicted to an extent within our results.
Even more interesting is the increased levels of activation seen with JAK3 within the KCL-22IR
cells. This finding is noteworthy due to the activation state of the common JAK3 substrate STAT5.
In the KCL-22IR cells STAT5 activation levels are nearly 33% the activation levels of STAT5
seen in the WT cell line. These results imply that activated JAK3 is not acting on STAT5.
Danial et al. demonstrated that within murine pre-B lymphocytes transformed with v-abl
constitutive activation of JAK-STAT signaling was present. Such findings have led several
scientist and clinicians to investigate the role of JAK inhibitors in treating drug resistant CML
patients (Warsch, 2013). Also interesting was the presence of decreased Shc activity seen in the
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KCL-22IR cells. Shc proteins are involved in regulation of apoptosis and are seen largely in drug
resistant cancers. Due to the high tolerance towards strong kinase inhibitors such as imatinib and
dasatinib, one would expect Shc activation levels to remain high within KCL-22IR cells. This
rationalization is contradicted with findings observed in our studies. Finally, ERK1/2 activity was
almost one-hundred times greater in the KCL-22IR cells compared to the KCL WT cells. As
described earlier, ERK1/2 serves major roles involved in cell survival and growth. Our results
support the findings demonstrated by Fenouille et al. which showed that Fyn/ERK kinase signaling
is increased in patient’s treated with imatinib. However, in their study, imatinib resistance was due
to increased Fyn/ERK activity in response to upregulation of a matricellular protein called
SPARC. Such protein activation changes have been shown to contribute to acquired imatinib
resistance, however our findings show that Fyn activity is decreased within the KCL-22IR cells.
Along with this, our KCL-22IR cells show extreme tolerance towards high levels of dasatinib,
which is a SFK (encompassing FYN) inhibitor, and shows inhibition of such proteins at
concentrations <10nM. These results suggest that Fyn may not be driving ERK activity. Another
important finding to realize is the raf-1 activity levels were significantly lower in KCL-22IR cells.
From the previous chapter we know that Raf activity is vital in the activation of it’s downstream
target ERK1/2. Finally, KCL-22IR cells showed increased levels of phosphorylated Itk, Tec, and
Zap70 in comparison to KCL-22WT.
In conclusion, increased ERK1/2, JAK3, and LYN activity demonstrated within our
imatinib resistant generated cell line has led us to conclude the possibility that the activation states
of these proteins is secondary to imatinib treatment, and possibly confers insensitivity to imatinib
and dasatinb. Based on the protein expression profiles demonstrated in figures 3.4 and 3.5. We
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have proposed KCL-22IR BCR-Abl signaling in the following flow diagram to illustrate pathways
altered in response to drug insensitivity (Figure 3.6).

Lyn

BCR-Abl

Intermediate

JAK3

ERK1/2

Drug Resistance

Figure 3.6 KCL22IR Utilizes JAK3 and/or ERK1/2 Signaling in Establishing Cell Survival.
Based on the phosphorylation profiles shown earlier, BCR-Abl may be utilizing JAK3 or ERK1/2
signaling through one or more intermediates.
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Chapter IV: Identification of Small Molecule Inhibitors that Selectively Induce
Cell Death in Imatinib Resistant Chronic Myeloid Leukemia
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4.1 Introduction
Recently, third generation kinase inhibitors are in phase III clinical trials for FDA approval.
One of these third generation kinases, Ponatinib (Iclusig, ARIAD) was developed with high
selectivity for the T315I BCR-ABL mutant. The FDA approved Ponatinib for the treatment of
chronic myeloid leukemia in December of 2012. However, in October of 2013, the FDA withdrew
it’s approval due to increased cardiac complications seen in CML patients treated with Ponatinib.
As of November 5, 2013, the FDA asked the manufacturer of Ponatinib to suspend all sales of the
drug. Ponatinib was a beacon for the treatment of T315I drug resistance seen in CML patients, and
it’s implications in clinical use could have been as monumental as Imatinib’s activity. Now that
Ponatinib has been discontinued for use in the clinic, a new therapy is now needed for the
treatment of drug resistant CML patients with the T315I mutation. Approximately fourteen years
have passed since the advent of TKIs in clinical usage. Much still remains to be explored about
these drugs mechanism of action within cancer. Using our imatinib resistant generated cell line,
KCL-22IR, we attempted to identify an already FDA approved small molecule inhibitor capable of
inhibiting a highly drug insensitive cancer. This approach allowed us to identify new pathways to
uncouple KCL-22IR cell line growth.

4.2 Materials and Methods
4.2.1 Proliferation Assays: Cells were cultured in complete media (previously described) with
Cmax concentration of respective drug. Cells were seeded at a concentration of 1.0 x 104 cells per
well in a 96-well plate. Plate was kept in incubation for 72-hours. After 72-hours, CellTiter96
Promega MTS Reagent was used, and manufacture protocol was followed. Plates were read using
a plate reader set to wavelength of 490nm.

59

4.2.2 Drug Concentrations: Imatinib and other kinase inhibitor concentration dose curves were
obtained from literature regarding phase I evaluations of each drug. Literature provided peak
concentrations (Cmax) values for each drug. Peak Concentrations for FDA approved drugs used in
primary dose curves were as follows: Imatinib (4,478.0 ng/ml) (Peng et al., 2004), Gefitinib
(443.88 ng/ml) (Milton et al., 2007), Dasatinib (46 ng/ml) (Demetri et al., 2009), Sunitinib (70.9
ng/ul) (Faiyre et al., 2006), Erlotinib (1,737 ng/ul) (Hidalgo et al., 2001), Lapatinib (2470 ng/ul)
(Chu et al., 2008), Nilotinib (3.6 uM) (DeRemer et al., 2008), Sorafenib (2,248 ng/ul) (Strumberg
et al., 2005), Trametinib (33.4ng/mL) (Infante et al., 2012), and Vemurafenib (61μg/mL) (Grippo
et al., 2013).

4.2.3 Statistical Analysis of Protein Activation: Statistics employed were performed utilizing
Minitab Statistical Software and SAS Statistical software.

4.2.4 Drug Treatments and Lysing of Cells: Cells were seeded at a concentration of 1.0 x 106 per
mL, and 5mLs was added to individual wells of a six well plate. Cells were left in culture with
designated concentrations of kinase inhibitors. After two hours, cells were harvested and
immediately lysed. Cell lysis buffer was supplied by Millipore Luminex Kit, and was
supplemented with complete protease inhibitors, n=3.

4.3 Results
4.3.1 KCL22-IR Cells Display Resistance Against Multiple Kinase Inhibitors
Cells were challenged against fifteen FDA approved small molecule inhibitors (Figure 4.1), the
majority of which are intended to treat other cancers besides CML. KCL-22R cells were also
tested against one experimental small molecule inhibitor, EP009. EP009 was developed within our
60

laboratory for the treatment of T-cell acute lymphoblastic leukemia by selectively targeting JAK3,
previously described (Ross, 2013). KCL-22IR cells’ IC-50 values were compared to KCL-22WT
cells and K562 BCR-Abl (+) cells. The KCL-22 imatinib insensitive clones demonstrated mark
resistance towards multiple kinase inhibitors (Figure 4.2a).

Figure 4.1 Schematic of Cell Signaling Pathways for Select FDA anti-neoplastics.
Kinases inhibitors are listed in red, and known target is referenced with red arrow. For
full detail on inhibitor, please see table 1 in appendix.
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Compared to the WT cells and K562 cells, the KCL-22IR cells demonstrated significant
insensitivity towards the majority of FDA approved kinase inhibitors. Inhibitors that showed the
most potency in inhibiting proliferation were ponatinib, temsirolimus, and nilotinib. However, the
concentrations of temsirolimus and nilotinib are in the upper range of peak clinical concentrations.
Interestingly, both WT and IR KCL-22 cells were markedly more sensitive to CP 690 550 than
K562 cells. However, IR cells displayed a higher insensitivity towards CP 690 550 than WT cells.
Trametinib, a MEK1/2 inhibitor displayed moderate potency towards all three cells, however IR
cells remained more insensitive to trametinib than both WT and K562 cells. Overall, cells showed
various levels of sensitivity towards different kinase inhibitors. Suggesting that specific proteins
are dominating proliferation machinery (Figure 4.2b).
4.3.2 KCL22-IR Cells Dependency on ERK1/2 Activity
Due to the results demonstrated in the previous chapter regarding increased ERK1/2
activation within KCL-22IR cells, and the results demonstrated in Figure 4.2a with KCL-22IR
cells demonstrating sensitivity towards trametinib (a MEK1/2 inhibitor), inhibitor influence on
activated proteins was investigated. Cells were treated with select inhibitors (Trametinib,
Dasatinib, Imatinib) with three dose points for approximately two hours. Starting with the first
dose point we began at 50% Cmax value and increased in equal increments according to
concentrations used in Figure20a. Cells were lysed according to manufacture protocol, and the
active states of forty-eight proteins in response to inhibitor treatment were analyzed (Figure 4.3).
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Figure 4.2 Multi FDA-Approved Drug Screen. K562, KCL-22- WT, and - IR cells were screened
simultaneously against various FDA approved kinase inhibitors. a.) MTS proliferation assays and cell
death % vs concentration of inhibitor. Max concentration was set to 110% Cmax values to insure
drug activity b.) Heat map of Cmax values for respective inhibitor (C Max only). Green: 100-60%-,
Black: 50%, Red: 40-0% CELL VIABILITY. N=3
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Figure 4.3 Select Kinase Inhibitors Influence on Active Proteins within KCL-22IR.
Cells were treated with increasing concentrations of dasatinib, imatinib, and trametinib.
Dose concentrations were as follows: 1st Dose Point = 50% cMax, 2nd Dose Point = 75%
cMax, 3rd Dose Point = 100% cMax of respective drug. Negative treatment corresponds
with cells that were only treated with DMSO, which all compounds were dissolved in,
n=1.

4.4 Discussion
Since imatinib was FDA approved for the treatment of CML over 10,000 patent
applications for kinase inhibtors have been filed (Akritopoulou-Zanze, 2009). This trend has not
declined, and in fact continues to grow. Unfortunately, the number of drug patents outnumbers the
number of drugs that successfully make it to market by a factor of twenty. Many factors make it
extremely difficult for one drug to be approved for clinical use. On average, it takes a
pharmaceutical company twelve years to get a new drug from the research lab to the patient (FDA
Special Consumer Report, 2013).
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Realizing this bottleneck in drug development, many have realized how imperative it is that
molecules that are already FDA approved be explored for potential utility in diseases that are
considered “off label”. Our results demonstrate support for such a rationale. Screening the KCL22IR cells along with the WT and K562 cells against various small molecule inhibitors revealed
potential candidate compounds for drug resistant and non drug resistant CML. For example,
although KCL-22IR cells are highly insensitive to imatinib and dasatinib, they displayed
sensitivity when treated with SNS-032, temsirolimus, and trametinib. All of which are being used
to treat other cancers besides CML. Both the WT and IR KCL-22 cells demonstrated increased
sensitivity towards SNS-032, compared to K562 cells, which indicates that the WT and IR cells
respond to changes made within cyclin protein activation. However, cyclin proteins serve many
roles in cell growth and development, and inhibition of these proteins can easily cause death in any
rapidly proliferating cancer (Galderisi, 2003). This was not the case in our studies, since K562
cells demonstrated cellular proliferation at a faster rate than both WT and IR KCL-22 cells (data
not shown). These findings suggest two conclusions. Cyclin activity is already at a minimal within
WT and IR KCL-22 cells or SNS-032 is cross-reacting with other key molecules present inside the
KCL-22 cells. Looking at figure 4.1 we can see that SNS-032 sensitivity is reduced in IR cells
compared to the WT KCL-22 cells, which indicates that other factors present within the IR cells
that are not present within the WT cells are influencing cellular proliferation to a greater extent.
From the last chapter, it was noted that in comparison to WT KCL-22 cells, the IR KCL-22 cells
displayed increased activation in ERK1/2 and JAK3, and decreased activation levels in BCR-Abl,
STAT5, and Raf-1. Our results demonstrate a unique finding in that although KCL-22IR cells
displayed higher levels of JAK3 activation, they were less sensitive to JAK3 selective inhibitors
such as EP009 and CP-690,550. However, both KCL-22 cell lines were more sensitive overall to
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these inhibitors when compared to K562 cells. These results suggest that both KCL-22 cells utilize
the JAK/STAT pathway to some degree, and that WT KCL-22 cells, despite not having high levels
of JAK3 activation, are more sensitive to inhibition of JAK/STAT signaling. Other interesting
finding involved the increased inhibition of proliferation due to MEK1/2 inhibition by trametinib.
Although the KCL-22IR cells demonstrated significantly increased ERK1/2 activity, they were
still more tolerant to trametinib treatment, compared to both KCL-22WT and K562 cells. These
results suggest that drug resistance may be conferred when there is no particular pathway
dependency, and multiple players besides a BCR-Abl mutant may be contributing to drug
resistance.
Lastly, our results also demonstrated that cell death in KCL-22IR cells is associated with
decreased levels in ERK1/2 activity, which was inhibited with increasing concentrations
trametinib, as seen in Figure 4.2. It is also worthy to mention that decreased activity in ERK1/2,
secondary to trametinib treatment, resulted in overall increased STAT5, p70S6K, and Akt
activation. The reverse was also seen when STAT5, p70S6K, and AKT activity were inhibited by
dasatinib treatment. However, when looking at figure 4.1 we can see that KCL-22R cells are
significantly tolerant to high concentrations of dasatinib, and therefore the results suggest that
STAT5, p70S6K, and AKT activity are not crucial for the survival of KCL-22R cells. In addition,
although lyn activity is greater in KCL-22IR cells in comparison to WT KCL-22 cells figure 3.4,
its inhibition via high concentrations of dasatinib are also not necessary for cell survival.
In conclusion these results demonstrate how small to large scale drug screens can be
utilized as a tool in investigating the proteomic landscape of a particular drug resistant cancer.
Secondly, these results prove how small molecule inhibitors can be used to treat cancers that they
were not originally intended to treat. Utilizing such drug screening methods within the clinical
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setting is of utter importance for the progression of cancer treatment, especially within patients
who have failed initial treatment options. Which in our proposed model we highlight a potential
pathway used by KCL-22IR cells (Figure 4.4)

Figure 4.4 Schematic of How KCL22-IR Cells Depend on ERK1/2 Activity to Circumvent
Drug Sensitivity. Within the KCL22-IR cells, inhibition of MEK1/2 (an ERK1/2 mediator)
induces cell death. Inhibition of other active proteins such as Akt, p70S6K, Lyn, and JAK3
does not induce cell death. Therefore the KCL22-IR cells rely on activated ERK1/2 and
possibly another intermediate in order to circumvent drug induced cell death.
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Chapter V: Genetic Alterations in Drug Resistant Chronic Myeloid Leukemia
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5.1 Introduction
Until now we have been concerned with the phenotype of drug resistant CML. The picture
would not be complete if we were to ignore what lies beneath the surface, such as the genetic
aberrations that are largely responsible for cancer promoting molecules. In recent years, data
acquired from global efforts at sequencing genomes of multiple organisms and individuals with
diseases has led to a vast amount of information regarding the genetic mutations that drive cancer
(Kim, 2013). In common tumors (colon, breast, brain, and pancreas) there exists an average of 33
to 66 genes with somatic mutations that can be labeled as potential culprits responsible for
damaged protein products. Depending on the extent and significance of such damaged proteins
determines whether or not these genetic aberrations will give rise to a tumor promoting protein.
The genome is a large set of information to navigate, and most sequencing efforts are interested in
analyzing only the exome. The exome is the collection of exons in the human genome. And exome
sequencing generally refers to the collection of exons that encode proteins (Vogelstein, 2013).
Due to advances in sequencing technology the cost to sequence an entire exome has
dramatically decreased. With such changes in affordability the generation of sequence variation
data is increasing at an exponential rate. To date, approximately 15-million single nucleotide
variations and one million short indels of the human population have been cataloged as a result of
the International HapMap Project and the ongoing 1000 Genomes Project. Bioinformatic tools
such as PROVEAN, SIFT, PolyPhen, MAPP, PANTHER, and ANNOVAR are being developed in
order to computationally predict the functional effect of sequence variations found within
sequencing data. Tools such as PROVEAN (Protein Variation Effect Analyzer) carry out it’s
function by utilizing a unique algorithm that predict functional impact for all classes of protein
sequence variations (including insertions, deletions, and multiple substitutions). In detail,
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PROVEAN utilizes pairwise sequence alignment scores in order to generate a “PROVEAN
Score”. Change in alignment scores can be easily interpreted as a possible impact factor for
protein function. PROVEAN measures the similarity of a protein variant to it’s functional
homologous counterpart before and after the introduction of the variant. Next it quantifies the
degree of impact of protein variant by analyzing variant frequency and chemical properties of
amino acid change. If the reference amino acid residue is found to be conserved and the variant
sequence alignment generates a low score (<-2.5), the variant will be assigned as having a
deleterious effect on protein function (Choi, 2012). Programs similar to PROVEAN, mentioned
earlier, perform similar functions in determining alterations within exome data.
Identifying and understanding genetic aberattions is extremely important for moving
towards targeted personalized medicine. Along with this, identifying genetic aberrations that may
coincide with drug treatment failure can potentially help limit costs and unnecessary suffering for
the cancer patient. It is with this objective that we aimed to use our highly drug resistant CML cell
line, KCL-22IR, as a model for how the genomic landscape can change as a cancer evolves.

5.2 Materials and Methods
5.2.1 Purifcation of Genomic DNA: Utilized Qiagen DNeasy Blood & Tissue Kit according to
manufacture’s protocol. DNA concentration was measured using NanoDrop 3000 (Thermo Fisher
Scientific, Inc., Wilmington, DE, USA), and was verified using 1% agarose gel (Ultra-pure
Agarose with 1x TBE) containing 0.002% EtBr.

5.2.2 Whole Exome Sequencing: Whole exome sequencing was performed at Otogenetics
Corporation (Norcross, GA, USA). Exome sequencing was performed utilizing Agilent
Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA, USA). Genomic DNA was
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subjected to multiple quality control checks performed by Otogenetics Corporation after which
Illumina libraries were generated from fragmented gDNA using NEBNext reagents (New England
Biolabs), and the libraries were subjected to exome enrichment using Agilent V4 (51 Mbp) kit.
Libraries were tested for enrichment by qPCR and for size distribution using Agilent Bioanalyzer
2100. After libraries were confirmed, samples were sequenced on a Illumina HiSeq2000 at a 30x
coverage. Sequence reads were aligned to the human genome reference sequence (build hg19) and
variants called and annotated using the DNAnexus software package.

5.2.3 Patient DNA Sequencing: Patient gDNA was sent for sequencing after gene amplification
was performed. Sequences were read using a 3130x/Genetic Analyzer (Thermo Fisher Scientific,
Inc., Wilmington, DE, USA) in the Border Biomedical Research Center housed at The University
of Texas at El Paso.

5.2.4 G-Banding Karyotype and SKY analysis: Chromosome analysis was conducted at the WiCell
Research Institute, WiCell Cytogenetics Lab, Madison, WI, USA.

5.2.5 BCR-ABL Kinase Domain Mutation Analysis: Cells were sent to Blood Center of
Wisconsin, Milwaukee, WI, USA, for interpretation of mutations identified within ABL kinase
domain. Analysis was carried out using RT-PCR followed by DNA sequence analysis of ABL
kinase domain covering amino acids 236-486. This region covers all the reported kinase domain
mutations. Sensitivity of mutation detection is approximately 20%. The clinical significance of
mutations present at <20% is not clear, according to BloodCenter of Wisconsin.
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5.2.6 Patient Samples: 56-Patient samples were randomly collected from a cancer specimen
repository. All patient samples were obtained under an approved Institutional Review Board
Protocol. The patient sample repository consists mainly of leukemia/lymphoma cancer patients
from within the Paso del Norte region. However, a small amount (less than 10%) of other cancers
such as pancreatic, brain, lung, and kidney cancers were available in the repository.

5.2.7 Generation of Bioinformatics Pipeline: Pipeline was adapted from the PROVEAN and SIFT
tool and was designed in collaboration with Dr. Ming-Ying Leung (Bioinformatics Program and
Mathematical Department at The University of Texas at El Paso), and UTEP Bioinformatics
Master candidate Joe Knapka. Primary functions of the pipeline were as follows:
1) Accept as input whole-exome sequence data as supplied by Otogenics Corp, in tabular commaseparated value format.
2) Compute protein variants for all isoforms of the genes affected by the SNPs and indels in the
input data.
3) Compute the PROVEAN score for each protein variant.
4) Query the PubMed database to discover any publications associated with each variant, based on
the dbSNP ID of the SNP (if provided) and the Human Genome Variation Society code for the
corresponding protein variant.
5) Find any Gene Ontology terms associated with each gene affected by the SNPs and indels in the
input data.
6) Assemble a final data set containing the input data with additional columns appended containing
PROVEAN score, Gene Ontology terms, and links to any PubMed references.
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7) Present a web service allowing sequence data to be submitted to the pipeline and results emailed
to the submitter.

5.2.8 Gene Amplification: Gene amplification was employed using polymerase chain reaction
(PCR). Primer sequences were obtained from NCBI primer blast tool, and were synthesized at The
Midland Certified Reagent Co., Midland, Texas, USA.

Gene

Forward 5’ to 3’

Reverse 5’ to 3’

FLT4

GATTGGTTCTTTCCTGTCTCTGA

CCACAAATATCAATTTACAACCATTG

ERBB3

TGACTGATTCCCCCAACCTT

ATCCCCATGCTTCACTCCAC

TNFRSF14 CCCTCTCTTCTCAGGCACCGAGAG GTGGAGCCCCCTCCCCAGGGCAC
NOTCH1

CCCTCGTTCTGTCGCCTG

CCATGGATGGCCAACACCAG

STAT5A

GTCCTTGTAAGCAGCCGCC

GCTGCCAACACTGAACTGAGA

PIK3CA

GATTGGTTCTTTCCTGTCTCTGA

CCACAAATATCAATTTACAACCATTG

5.2.9 Gene Mania: GeneMANIA locates other genes that are related to a set of input genes, using a
very large set of functional associations. (GeneMANIA is actively developed at the University of
Toronto, in the Donnelly Centre for Cellular and Biomolecular Research, in the labs of Gary Bader
and Quaid Morris. GeneMANIA development was originally funded by Genome Canada, through
the Ontario Genomics Institute (2007-OGI-TD-05) and is now funded by the Ontario Ministry of
Research and Innovation).
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5.3 Results
5.3.1 Identification of T315I BCR-Abl Mutant Within KCL-22IR Cells
During cloning process of KCL-22IR cells, IR cells were sent for whole exome sequencing.
Cells were also sent for SKY and G-banding Karyotyping analysis, along with in depth analysis of
BCR-ABL kinase domain mutation analysis. Karyotyping revealed an abnormal karyotype with
complex and numerical aberrations including the t(9;22) consistent with CML. The predominant
clone (seventeen out of twenty cells) is shown in (Figure 5.1a). The predominant clone included
eight structural abnormalities, an extra copy of the Philadelphia chromosome, trisomy 6, and
tetrasomy 8. Two subclones were also identified with the same structural aberrations of the
predominant clone. One subclone additionally had four copies of chromosome 6 and five copies
of chromosome 8. The other subclone had four copies of chromosome 6, a structural aberration in
one chromosome 6, and a derivative chromosome 18 resulting from an unbalanced translocation
between chromosome 5 and 18 (these clones made up 5% of the population). Detailed karyotype
results included:
50~54,X,del(X)(p11.4p22.2),+der(1;10)(q10;p10),dup(2)(p13p21),+6,+8,+8,t(9;22)(q34;q11.2),
der(17;19)(q10;q10),+19,der(19)t(3;19)(q25;q13.1),i(21)(q10),+der(22)t(9;22)[cp17]/.
55,idem,+6,+8[2]/. 51,idem,+6,add(6)(q13),der(18)t(5;18)(p13;p11.2)[1*]
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Figure 5.1 Karyotyping and ABL Kinase Domain Analysis. a.) T(9;22) identified
along with trisomy 6, tetrasomy 8, and an extra Ph+ chromosome. b.) T315I mutation
was detected in approximately an equal amount to the normal allele. Overall, karyotype
was abnormal with significant alterations highlighted with red arrows.
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BCR-Abl kinase domain analysis identified a mutation in the BCR-ABL kinase domain. The
T315I mutation was detected in approximately an equal amount to the normal allele. Two minor
variants were detected. One variant c.1087_1088delGA had a frameshift mutation starting at
aspartate 363 and continued for 18 codons resulting in a truncated protein. The clinical
significance of this mutation and whether it is responsible for imatinib resistance is unknown.
However we are further investigating whether any of our clones possess this variant. A 35-bp
insertion at the junction of exon 8 and 9 was detected that causes premature truncation of the
protein that includes part of the kinase domain (Laudadio et al, J Mol Diagn 2008, 10:177-180).
The insertion appears to be caused by alternative splicing of the 35-bp sequence from intron 8.
This mutation is frequently found in imatinib-resistant patients and there is preliminary evidence
that the mutation may cause imatinib resistance, computer predicted only, (Lee et al, Mol Cancer
Ther 2008 7:3834-3841) but this has not been confirmed in the published literature.

5.3.2 Identification of Various Genetic Alterations within WT and IR KCL-22 Cells
Along with ABL kinase domain analysis, IR cells were sent to Otogenetics Corporation for
whole exome sequencing. Generated IR clones from chapter one were sent for whole exome
sequencing as well as WT KCL-22 cells. Sequencing results were analyzed utilizing a custom
bioinformatics pipeline adapted (as described in methods) from the PROVEAN program. SIFT
was also employed alongside PROVEAN in order to ensure validity of results. PROVEAN and
SIFT programs together identified more than 100-deleterious (PROVEAN) and 100-damaging
(SIFT) genetic variations within the KCL-22R (T315I) cells, as compared to the <80 variants
found within the WT cells (Table 2 Appendix).
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5.3.3 Clarification of Selected Genetic Variants within KCL-22IR Cells
Identified variants were narrowed down to a selected number based off of PROVEAN and
SIFT scores. PROVEAN scores and SIFT scores were made stringent, by lowering PROVEAN
score, in order to decrease likelihood of false interpretations (Table 5.1). Identified genes using
this approach were then queried for biological associations using GeneMANIA. Utilizing this tool
we were able to summarize associations amongst genes listed by our bioinformatics pipeline
(Figure 1 Appendix). Next genes were chosen based on two criteria: 1.) They were not
significantly involved within the same molecular pathways. 2.) Their variant must have occurred
within a vital region of the protein, such as a DNA binding domain, tyrosine kinase domain, or
other conserved region. Such rationale was used in order to obtain a broad set of genes involved in
multiple pathways. Six genes were finally arrived at which were PIK3CA, FLT4, ERBB3,
TNFRSF14, NOTCH1, B-Raf, and STAT5A. gDNA was obtained from KCL-22IR cells in culture
and respective genes were amplified in order to verify findings obtained from whole exome
sequencing and PROVEAN/SIFT scores (Figure 5.2a). Sequencing results demonstrated that gene
variants were present within KCL-22IR genome, and were confirmed using both forward and
reverse primer sets.

5.3.4 Identification of FLT 4 Variant within Random Patient Cancer Samples
After clarifying variants identified through bioinformatics pipeline and whole exome
sequencing, 56 random cancer patient samples were obtained (samples consisted mainly, 90%, of
leukemia and lymphoma cancers, and the remaining cancers varied between brain, lung, and
pancreatic cancers). GDNA was purified from these patients. The 6 identified gene variants were
amplified in 10-patients to determine frequency of mutations. Of the 6-identified genes, nucleotide
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alterations which led to a FLT4 H890Q variant was identified and confirmed within two of the first
10-patients. FLT4 was then the only gene used in screening the remaining 46 patient samples. Of
the complete 56 random cancer patients, 13 patients (23% of patients) displayed the FLT4 H890Q
mutation (Figure 5.2b).

Table 5.1 Genomic Variants Identified as Potential Leads
GENE
ABL1
ARID2
AXL
BRAF
BRCA1
CDH1
ERBB3
FGFR4

Variant
T334I
A1739V
R217H
H608Y
E1038G
P170L
G854S
T262K
P683L
FLT4
H890Q
GNA11
Q209H
GPR124
C218F
S535L
IKZF1
C150Y
IRS2
D1257H
KEAP1
L365Q
MST1R
M1196I
NOTCH1
G1195R
PDGFRB
R456S
PIK3CA
E545G
STAT5A
G431C
TET2
P50R
TNFRSF14 G174W
ZNF703
P284L

PROVEAN Score
-5.722
-2.652
-3.114
-2.581
-5.783
-8.286
-5.329
-3.912
-9.146
-5.137
-4.814
-8.654
-3.463
-9.678
-3.473
-4.939
-3.868
-7.398
-3.092
-5.866
-7.99
-3.105
-6.046
-2.815

Interpretation
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
Deleterious
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SIFT Score
0.002
0.001
0.003
0.027
0.044
0.001
0
0.001
0
0.045
0.007
0
0.002
0.001
0.007
0.001
0.009
0.023
0.032
0.001
0.001
0.002
0.001
0.355

Interpretation
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Damaging
Tolerated
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Figure 5.2 Chromatograph of Sequencing Results. a.) Variant clarification (red
arrows) in KCL-22IR cells, and respective amino acid changes. b.) Patient variant
clarification of FLT4 H890Q variant. Thirteen of the fifty-six patients displayed this
FLT4 H890Q variant (red arrows). These results demonstrate that this mutation is not
limited to a laboratory established cell model, but may also serve a role in clinical
disease. The FLT4 H890Q variant occurs within the kinase domain of the protein, and is
expected to be damaging to protein function as predicted by our bioinformatics program
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5.4 Discussion:
Navigating the genomic landscape of cancer remains to be a challenging task. Improved
technology and new bioinformatics tools such as PROVEAN are helping pave the way for a better
understanding of the genetic underlying of cancer. However, we still have further to travel to fully
utilize information obtained from a patient’s genome in designing a personalized therapy. Such
findings as the ones we have demonstrated serve as a “proof of concept” for how bioinformatics
tools can be utilized to assess damaging mutations within a patient’s exome. The results presented
in Figure 5.3 highlight how more than one mutation may be driving drug resistance in KCL-22R
cells. After performing an analysis of the whole exomes of both KCL-22WT and IR cells, there
were several fold more mutations present within the IR(T315I) versus the WT(Parent) KCL-22
cells. Such findings are significant for future clinical use of whole exome screening of cancer
patients. For example, it would be advantageous for the clinician to identify genetic alterations that
may lead to drug resistance before starting a patient on a treatment regime. Besides these findings,
our results reveal numerous novel mutations (all with significant PROVEAN/SIFT scores). In the
past, it was commonly held that such mutations were caused by exposure to the drug itself.
However today that rational is losing support. Instead, novel mutations present within drug
resistance cancers are being attributed to small populations of opportunistic cancer mutants that
remain dormant, but become active in favoring conditions. Finding ways of identifying such
minute populations of highly malignant cancer cells is of extreme importance. The mutations
identified within Table3 may prove interesting when fully characterized with complete protein
analysis, and may lead to data that would shine new light on how drug resistance is acquired
within CML. Not only will these findings only apply to CML treatment, but will also prove useful
towards understanding cellular mechanisms present in other cancers.
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Figure 5.3 Circos Diagram of Genetic Alterations Present in Both Parent and T315I
KCL-22 Cells. This diagram gives a graphic representation of the magnitude of genetic
alterations seen in the KCL-22IR (T315I) cells in comparison to the parent (WT) cells.
Larger ribbons indicate more mutations are present within respective (connecting)
chromosome. Size of chromosome band indicates number of mutations overall (both WT
and IR cells) found within chromosome. As shown, T315I resistant cells demonstrate a
much larger array of mutations in comparison to the parental cells.
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Chapter VI: Overview
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In summary, our study has led to the generation of a T315I CML cell line, KCL-22IR,
which shows high drug insensitivity towards first and second generation kinase inhibitors. Such a
cell line will prove useful in future studies involving high throughput drug screening, and cell
signaling studies investigating acquired drug resistance within cancer. Our study has also revealed
non-CML cancer drugs efficacy in inhibiting T315I CML mutants. Such findings are significant,
and demonstrate that drug resistant cancers can potentially be treated successfully if the cancer
cells are screened against various drugs in vitro, ultimately saving the patient time and side effects.
We also revealed novel activation states in key molecular pathways that coincide with CML drug
resistance. Along with these findings, our study highlighted the protein ERK1/2 as being integral
to T315I CML survival. For future directions, investigating the mechanisms of how ERK1/2 is
regulated by BCR-Abl will be of interest. Our studies highlighted that activated Raf (an upstream
modulator of ERK1/2) is not necessary for ERK1/2 activity. Identifying why this anomaly is
occurring will prove interesting in future studies. ERK1/2 serves as a potential therapeutic target in
our T315I drug resistant CML cell line, and can possibly be utilized in combination therapies. For
example, Khateb et al. demonstrated that allosteric and ATP competitive inhibitors in combination
can be utilized in overcoming BCR-Abl T315I CML, however the allosteric inhibitors reported
within this study are not yet FDA approved. From our screening results we demonstrated that
inhibition of mTOR can also induce cell death. One future aim would be to utilize FDA approved
ERK1/2, MEK1/2, and mTOR inhibitors (such as Trametinib and Temsirolimus) in combination
against our T315I drug resistant CML cell lines. Performing such experiments will prove useful for
both scientists and clinicians in identifying a therapy that utilizes FDA approved compounds in
combating drug resistant cancers. Finally, we have illustrated results from a bioinformatics
pipeline that is capable of accurately predicting genetic variants from whole exome screening
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results. We generated a list of over a hundred different variants impacting kinases, phosphatases,
and transcription factors that are present in our T315I CML cell line. Future directions can be
aimed at characterizing such variants, and their implications in the general patient population. As a
“proof of concept”, within our presented study we have already performed this by partially
illustrating the abundance of a novel FLT4 H890Q mutation within leukemia patient samples. In
conclusion, our study has illustrated how T315I drug resistant CML may rely on ERK1/2 activity
for survival, and BCR-Abl may utilize multiple intermediates in the process of insuring constant
ERK1/2 activity (Figure 6.1).
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Figure 6.1 Schematic of BCR-Abl Modulation of MEK1/2 and ERK1/2 Activity within
KCL22-IR T315I CML Cell Line. BCR-Abl utilizes MEK1/2 or ERK1/2 activity to
ensure cell survival, and may be doing so either directly or through the utilization of an
intermediate. Such an intermediate may be present within the multitude of genomic variants
that were identified in our present study.
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Appendix

Table 1 List of FDA Approved Drugs Screened against KCL-22 Cell Line.

DRUG
Dasatinib

Imatinib

Sorafenib

Vemurafenib

Trametinib
Pimozide
Sunitinib

CP 690 550
Nilotinib
Gefitinib
Lapatinib

USAGE
CML, Endometrial Clear
Cell Carcinoma
(Phase2), Prostate
Cancer (Phase2).
CML, Gastrointestinal
stromal tumor,
Liposarcoma
Desmoid Tumor,
Hepatopulmonary
Syndrome,
Hepatocellular
Carcinoma, Renal Cell
Carcinoma
Neoplasms, Multiple
Myeloma (Phase2)

Melanoma (Phase2),
Cancer General
Antipsychotic Agent,
Tourette’s Disorder
Breast Cancer (Phase1),
Melanoma,
Genitourinary Cancer
Rheumatoid Arthritis
CML, Gastrointestinal
Stromal Tumors
Non-Small-Cell Lung
Cancer, Lung Cancer
HER2+ Metastatic
Breast Cancer, Recurrent
Thyroid Cancer, Breast
Cancer, Breast
Neoplasms

TARGET
Abl, Src, c-Kit (D816V/WT)

PDGFR, c-Kit, v-Abl

Raf-1, VEGFR2/FLK1, B-Raf
(V599E), PDGFRb, FLT3, c-Kit,
VEGFR2, FGFR1

SRMS, ACK1, B-Raf (V600E), CRaf, KHS1(MAP4K5), Lck, BRK,
NEK11, BLK, Lyn B, Yes1, WNK3,
Src
MEK1, MEK2
Dopaminergic receptors, STAT5
PDGFRb, VEGFR2, FGFR1, EGFR

JAK3, JAK2, JAK1, ROCK2, LCK,
Bcr-Abl
EGFR, ErbB2, ErbB4, c-Src
EGFR, ErbB2, ErbB4, c-Src
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Temsirolimus

SNS-032

EP009
INCB018424

Ponatinib

Cervical
Adenocarcinoma,
Ovarian Clear Cell
Cystadenocarcinoma,
Neuroblastoma,
Endometrial
Adenocarcinoma
B-Lymphoid
Malignancies (Phase1),
Tumors (Phase1)
Experimentally
demonstrated in T-ALL
Primary Myelofibrosis,
Metastatic Pancreatic
Adenocarcinoma,
Atypical CML, CLL
(Suspended) Ph+ ALL,
GIST, Adenocarcinoma
of the Lung

mTOR

CDK9/CyclinT, CDK2/CyclinA,
CDK2/CyclinE, CDK7/CyclinH,
GSK-3a, CDK5/p35, CDK1/CyclinB,
GSK-3b, CDK4/CyclinD
JAK3
JAK1, JAK2

Abl, PDGFRb, VEGFR2, FGFR1, cSrc, c-Kit
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Table 2 Genomic Variants Identified in KCL-22 Imatinib Resistant (T315I) Cell Line.

Gene

Chromosome

ABL1

9

ALK

2

APC
AR
ARID2
ASXL1

5
X
12
20

ATM
ATR

11
3

AURKA

20

AURKB
AXL

17
19

BCL2L2
BCOR
BCORL1
BRCA1

14
X
X
17

BRCA2

13

T315I
Variant

Zygosity

T334I
A537_V538insGCEYL
E810G
R804_L805insGW*K
S1018P
T333I
T315I
D1529E
K1491R
I1461V
V1763D
E81Q
A856V
A654_T655insGHR*
P874L
L815P
N1635S
M211T
V2250A
F31I
I57V
M299T
R217H
N266D
Q133R
V878A
F111L
A1502V
K1183R
E1038G
P871L
I180N
N289H
N991D
V2466A

Het
Het
Het
Het
Het
Het
Het
Het
Het
Hom
Hom
Het
Het
Het
Het
Hom
Hom
Het
Het
Het
Hom
Hom
Het
Hom
Hom
Hom
Hom
Het
Het
Het
Het
Het
Het
Het
Hom
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Gene

Chromosome

BRIP1
CCND3
CDH1
CHEK1
DOT1L
EGFR
ERBB2

17
6
16
11
19
7
17

ERBB3
ETV1
ETV5
EWSR1

12
7
3
22

FANCA

16

FANCD2

3

FANCE

6

FBXW7
FGF23

4
12

FGF4
FGFR2
FGFR3
FGFR4

11
10
4
5

T315I
Variant

Zygosity

S919P
S63A
P170L
I437V
V1418L
R521K
A37T
I655V
P1170A
G854S
S60G
A177P
R603W
R615Q
G809D
G501S
T266A
N405S
P672L
V725A
R343Q
M487T
N71D
T239M
R175W
S127R
M71T
V411M
V10I
T150K
Q189K
G388R
P455L

Hom
Het
Het
Hom
Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Hom
Hom
Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
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Gene

Chromosome

FLT3
FLT4
GNA11
GNA13
GNAQ

13
5
19
17
9

GPR124

8

IKBKE
IKZF1
IL7R

1
7
5

IRS2

13

JAK3
KDM5A
KDM5C

19
12
X

KEAP1
MCL1

19
1

MEN1

11

MLH1

3

T315I
Variant

Zygosity

T361R
D363E
P136L
T227M
H890Q
Q209H
K42_T43ins
Y101*
T96S
C218F
S535L
V806M
R963G
S698L
A602V
A10T
I66T
V138I
R1259K
V1258L
D1257H
G1057D
L1060M
M865T
Y751H
G249A
L365Q
E124K
E124K
T541A
W423*
T541A
L161S
L259S

Het
Het
Hom
Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
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Gene

Chromosome

MSH6

2

MST1R

3

MTOR

1

MUTYH

1

MYCN

2

NOTCH1

9

NOTCH2

1

NTRK1

1

PDGFRA
PDGFRB
PHF14
PIK3CA
PIK3CD

4
5
7
3
1

PIK3R1

5

T315I
Variant

Zygosity

F1088_F1088del
G39E
E1091D
M1090I
M1090I
E1091D
S1089G
P1254T
M825I
S275T
S275T
M825I
P1254T
I510L
I520L
V408M
V408M
G1195R
G1195R
T311P
H1190P
E38K
C19W
A14V
G151R
G151R
S478P
R456S
K115R
E545G
T421A
M786I
M56I

Het
Hom
Het
Het
Het
Het
Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
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Gene

Chromosome

PIK3R2
PMS2

19
7

PRKDC
PTPN13
PTPN14
PTPN23

8
4
1
3

PTPRD
RET
RICTOR
RNF43

9
10
5
17

SETD2

3

SOCS1

16

SOCS3

17

SPEN

1

SPRED2
SPRY2
STAT3
STAT5A
TET1

2
13
17
17
10

T315I
Variant

Zygosity

S313P
K541E
T485K
I166_P167insYQIQF*
C594Y
Y165H
L647_D648delinsFY
A944T
L1119M
S887*
D489N
S837F
L418M
R117H
I47V
G1231E
M1080I
L200I
A44T
H4Q
T3R
A970V
L1091P
A2105_A2106ins
N2360D
Q2413*
N321K
P106S
Q829*
G431C
D162G
I1123M

Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Hom
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Hom
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Gene

Chromosome

TET2

4

TET3

2

TNFRSF14

1

TSC2
TSHR
WISP3
ZNF217
ZNF703

16
14
6
20
8

T315I
Variant

Zygosity

P29R
F868L
I1762V
G1861_V1862insEWPWLQLM
A163V
Q1163*
Y26C
G174W
S1621L
R269S
Q74H
T548I
A28V
P284L

Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
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Table 3 Genomic Variants Identified in KCL-22WT (Parent) Cell Line.

Gene

Parent
Variant

Chromosome

ABL1

9

BLM

15

BRCA2

13

GRIN2A

16

MUTYH

1

PRKDC

8

A841_L842insP
A846_A847insSRWP
L805_V806insMRK
L842_G843insAPSPRAWSWTAPRRCASPS
L860_G861insAPSPRAWSWTAPRRCASPS
S517_S518insKPNLPMILIILT*
P521_G522insYMSLQ*
E1441_N1459del
N1463_N1463del
E1465F
I1470_R1471insF
R1471_K1472insT*SKKMA*RRNI*WST
M1475_D1476delinsYCRLCRKLFV*
L1478_S1479ins**FRIS
T1483_D1484insC*RSKKH*FFQSNIQCKRCKCIP
K1489_K1489del
L1491_N1501delinsYR
G1529_K1530insN*
K1531_K1533delinsQRE*
A1535_V1542del
C1573_K1574insS*VSLI
L1576_A1579delinsF*HSKWKI
C1591_S1676del
S1682_S1682delinsF*NRR*Y
F1396_F1396delinsSCQTT
Q1398_G1399delinsPIT
S1501_N1502insLMLQIRIICTLPPGF*IPAAIDACTRKCLV
R1503_K1508delinsL
P1510_*1517delinsFX
I383L
I509L
I417L
K216_L217insLCSIQLRHICHLLCLQ*V
L217_P218insILPRFSV*
L220_A221insKEQGLRSSHET*
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Gene

Parent
Variant

Chromosome

PTPN13

4

PTPN23

3

PTPRD

9

RPTOR
SPEN

17
1

F234_T235insWRIRRPPWD
K236_S237insRLGRW*
R246_E247insDY
E247_I248insTVSRGDF
I248_F249insPHDKRDLFRSLLAVHQLDQP*
P258_Q259insV
Q259_I260insRANRRV**AGDSHGVSAKA
L274_F275insEDEYKP*GFPGAP
A276_L277insSANSPVYQSDVT*
H278_C285del
K374_E387del
I389_I389del
C392_K393insL
Y799_L1198del
S1203_S1203del
N1205_L1206insQHPWQ
R264_Y265insYCYLEGPSFEHHVP
A29V
C594Y
A29V
C594Y
A29V
A1002T
A818T
L993M
S887*
S890*
V291M
L1090P
A2104_A2105insLQHRQGRGNLGW*
A2106_Q2107insSETQTRKWWLL*R
E2110_E2110delinsGSHT
S2125_P2126insRVLMKTVGSTQGPCL*

112

Zygosity
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het
Het

Gene

Parent
Variant

Chromosome

TET2

4

TNK1

17

TP53

17

P2688_L2692delinsSCF
S2769_V2953del
N2956_S3024del
G3029_G3029delinsSHTLSFPPLPLLACL
S3042_S3043insRRQRGPRRE*
T3044_A3148del
H3153_P3154insLDLQTG
P3154_P3155insLSLTPRFRGHKQKQARLPS
E3156_H3162delinsLCLSP*SLTFQSLFPLR
A3168_Q3173delinsCL
E3175_P3225del
G3229_P3254del
P3343_Q3357delinsS
Q3360F
A3362_P3364delinsTL
Q3449_Q3449delinsCCRSSRPVSSLRV
A3451_Q3478delinsC
P3481_K3482insW
E3541_P3545del
E3632_*3664delinsX
N2359D
A2066_Q2067insSETQTRKWWLL*R
E2072_E2072delinsAPLLR*Q
V2075_V2076insSQGRRSHGLSLLH*
E1909_E1909delinsPMAKK*
H1912_G1913insGPCP*PQTPQ*L
G1913_L1914insLHMPSLGSQ
V598M
V593M
P142_G143insQGALSEHC
Q216_S217insLT
S217_S217del
S219_*235delinsX
P169Q
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Gene

Parent
Variant

Chromosome

S171_R174del
T180_S181insISPFRCYLTYDGV
P262Q
P270_N271insSEHC
N179_T180del
A232_K240delinsQ
S244_S244del
P309_N310insSEHC
N310_N311insTTPAPLPSQRR
N311_T312insHWME
P72R
S283_T284insV
T284_K285insASRCSES*
K285_R286insPAT*SP
A287_A287delinsVS
W338_*347delinsRX
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Figure A1 Gene Mania Results of Associations Between Lead Genomic Variants.
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